Document:

EX-10.16

 Exhibit 10.16 

FIRST AMENDMENT TO SUBLEASE 

THIS FIRST AMENDMENT TO SUBLEASE (“Amendment”) is made and entered into as of the 24 day of August, 2018, by and
between THE MEDICINES COMPANY, a Delaware corporation (“Sublessor”), and GOSSAMER BIO, Inc., a Delaware corporation (“Sublessee”). 

R E C I T A L S : 

A. Sublessor and Sublessee entered into that certain Sublease dated as of December 29, 2017 (the “Original Sublease”) as
amended by that certain Acknowledgement of Commencement Date and Expiration Date dated as of February 9, 2018 (“Commencement Memo”), whereby Sublessee Subleased certain space in the building located at 3013 Science Park Road,
San Diego, California 92121 (the “Building”). The Original Sublease, as amended by the Commencement Memo, is referred to herein as the “Sublease.” 

B. By this Amendment, Sublessor and Sublessee desire to expand the Premises and to otherwise modify the Sublease as provided herein. 

C. Unless otherwise defined herein, capitalized terms as used herein shall have the same meanings as given thereto in the Original Sublease.

 NOW, THEREFORE, in consideration of the foregoing recitals and the mutual covenants contained herein, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 
 A G
R E E M E N T : 
 1. The Existing Premises. Sublessor currently subleases to
Sublessee that certain space containing approximately 32,039 rentable square feet located on the second (2nd) floor of the Building and known as Suites 200 and 250 (the “Existing Premises”). 

2. Expansion of the Premises. That certain space consisting of the entirety of the first (1st) floor of the Building and consisting of
approximately 31,628 rentable square feet is referred to herein as the “Expansion Space.” The Expansion Space includes a vivarium consisting of approximately 4,052 rentable square feet (the “Vivarium”), which space
will be delivered to Sublessee in advance of the Expansion Commencement Date, as more fully set forth in Section 3 below. The Expansion Space, exclusive of the Vivarium, contains approximately 27,576 rentable square feet, and such portion of
the Expansion Space may be referred to herein as the “Remainder Space.” Sublessee shall sublease the Remainder Space effective as of the date (“Expansion Commencement Date”) that is the earlier of (a) the date
Sublessee commences business operations in the Remainder Space, or (b) January 1, 2019. Accordingly, effective upon the Expansion Commencement Date, the Existing Premises shall be increased to include the Expansion Space. Such addition of
the Expansion Space to the Existing Premises shall, effective as of the Expansion Commencement Date, increase the number of rentable square feet subleased by Sublessee to include the entire Master Premises leased by Sublessor pursuant to the Master
Lease. Except as provided in Section 3 below as to the Vivarium, Sublessor will not be in default under this Amendment if the Expansion Commencement Date is delayed for any reason. Effective as of the Expansion Commencement Date, all references
to the “Premises” shall mean and refer to the Existing Premises as expanded by the Expansion Space. 

  

 3. Vivarium. Sublessee desires access to the Vivarium as soon as reasonably
practicable after the full execution and delivery of this Amendment. Accordingly, the Vivarium will be delivered to Sublessee on the date (“Vivarium Commencement Date”), which is the later of (i) the full execution and delivery
of this Amendment and (ii) receipt of Lessor’s consent to this Amendment. In the event the Vivarium has not been delivered to Sublessee by September 1, 2018 (the “Target Delivery Date”), which date shall be extended by any
Force Majeure events or delays caused by the acts or omissions of Sublessee, then Sublessor will provide Sublessee with a rent credit equal to one day of Base Rent plus Operating Expenses, Amenities Fees and Taxes attributable to the Expansion Space
for each day of delay; provided that the maximum rent credit to which Sublessee is entitled hereunder shall be thirty (30) days, regardless of when the Vivarium is delivered. Any rent credit will be applied to Sublessee’s obligation to pay
Base Rent and Operating Expenses, Amenities Fees and Taxes hereunder commencing as of the Expansion Commencement Date. For example, if the Vivarium is delivered on September 10, 2018, then Sublessee will be entitled to a rent credit equal to
ten (10) days of Base Rent and Operating Expenses, Amenities Fees and Taxes for the Expansion Space only, which rent credit would be applied to the first ten (10) days of the Expansion Space Term. Notwithstanding the foregoing, if the
Vivarium has not been delivered to Sublessee within thirty (30) days after the Target Delivery Date (as the same may be extended), then at any time thereafter and before delivery of possession of the Vivarium to Sublessee, Sublessee may give
written notice to Sublessor of Sublessee’s intention to cancel this Amendment as to the Vivarium only (i.e., the Sublease will remain in full force and effect as to the Remainder Space and the Existing Premises and only the Vivarium will be
excluded). Said notice shall set forth an effective date for such cancellation which shall be at least five (5) business days after delivery of said notice to Sublessor. If the Vivarium is delivered to Sublessee on or before such effective
date, this Sublease shall remain in full force and effect as to the Vivarium and Tenant’s termination notice will be revoked. If Sublessee exercises the foregoing termination right as to the Vivarium, the Base Rent, Sublessee’s Pro Rata
Share and the Security Deposit will be adjusted accordingly, all references to the “Expansion Space” shall mean and refer to the Remainder Space only, and neither party will have any further liability to the other on account of such
termination. Sublessee will not be permitted to use the Vivarium unless and until it provides proof of insurance meeting the requirements of the Sublease applicable to the Vivarium (and any delay caused by Sublessee’s failure to obtain
insurance will not result in any rent credit). 
 4. Early Access. Sublessor will allow Sublessee access to the Remainder Space
(except for Suite 150) from and after the Vivarium Commencement Date and continuing through the Expansion Commencement Date, and will allow Sublessee access to Suite 150 from and after November 1, 2018 and continuing through the Expansion
Commencement Date (“Early Access Period”) for the sole purpose of performing any initial improvements and installation of furniture, fixtures, equipment or other leasehold improvements including but not limited to telephones,
computer wiring and networking cable (provided that Sublessee will obtain the prior consent of Lessor and Sublessor to such items to the extent required by the Master Lease or this Sublease). Sublessee shall not be obligated to pay any Base Rent or
Operating Expenses for the Remainder Space during the Early Access Period, but will be responsible for the payment of utilities for the Remainder Space commencing as of the first day Sublessee accesses the Remainder Space. Utility 

  
 -2- 

 costs for the Remainder Space during the Early Access Period will be
pro-rated between Sublessee and Sublessor based upon the approximate rentable area of the Remainder Space each party has the right to use in relation to the total rentable area of the Remainder Space, as
reasonably determined by Sublessor. Sublessee will not be permitted to enter the Remainder Space unless and until it provides proof of insurance meeting the requirements of the Sublease applicable to the Remainder Space (but failure to provide proof
of insurance will not affect Sublessee’s obligation to pay utility costs). Notwithstanding the foregoing, in the event that Sublessor has not tendered delivery of the Remainder Space to Sublessee on or before November 1, 2018 (the
“Outside Date”), which date shall be extended on a day for day basis by delays caused by Sublessee’s acts or omissions (including, without limitation, failure to provide proof of insurance) or Force Majeure events, then as
Sublessee’s sole remedy, Sublessee shall receive one (1) day of Base Rent abatement for each day after the Outside Date (as extended) until the date Sublessor tenders delivery of the Remainder Space, which abatement shall be applied to the
monthly Base Rent otherwise payable for the first (1st) month after the Expansion Commencement Date. 
 5. Expansion Space Term.
Sublessee’s lease of the Expansion Space shall commence on the Expansion Commencement Date and shall continue until December 31, 2022 (“Expansion Termination Date”). Tenant hereby acknowledges and agrees that Tenant’s
lease of the Expansion Space is not coterminus with Tenant’s lease of the Existing Premises. The period from the Expansion Commencement Date through the Expansion Termination Date shall be referred to herein as the “Expansion Space
Term.” 
 6. Monthly Base Rent. During the Expansion Space Term, Sublessee shall pay Monthly Base Rent for the Expansion
Space only as follows: 
  

													
	 Period of

Expansion Space Term
	  	 Approximate

Square Footage
 of
Expansion
 Space
	 	  	Monthly Base Rent	 	  	 Monthly Base Rent Per

Rentable Square Foot
	 
	 Vivarium

Commencement Date – Expansion

Commencement Date
	  	 	4,052	 	  	$	14,992.40	 	  	$	3.70	 
	 Expansion

Commencement Date –

1/31/19
	  	 	31,628	 	  	$	117,023.60	 	  	$	3.70	 
	 2/1/19 – 1/31/20
	  	 	31,628	 	  	$	120,502.68	 	  	$	3.81	 
	 2/1/20 – 1/31/21
	  	 	31,628	 	  	$	124,298.04	 	  	$	3.93	 
	 2/1/21 – 1/31/22
	  	 	31,628	 	  	$	127,777.12	 	  	$	4.04	 
	 2/1/22 – 12/31/22
	  	 	31,628	 	  	$	131,572.48	 	  	$	4.16	 

  
 -3- 

 *Plus any partial month at the beginning of the Expansion Space Term if the Expansion Commencement Date is
not the first day of the month. Base Rent payable pursuant to this Amendment will not be subject to abatement, notwithstanding any rent abatement provided in the Original Sublease. Base Rent for the Existing Premises shall continue to be payable in
accordance with the provisions of the Sublease. Although monthly Base Rent for the Existing Premises shall be calculated separately from the Base Rent for the Expansion Space, Base Rent for the entire Premises shall be a single, non-severable obligation. 
 7. Additional Rent. Effective as of the Vivarium Commencement Date,
Sublessee’s Pro Rata Share for purposes of Section 6(C) of the Original Sublease will be increased to 57.29% (subject to adjustment in the event of a remeasurement of the Building or Premises pursuant to the Master Lease). Effective
as of the Expansion Commencement Date, Sublessee’s Pro Rata Share will be increased to 100%. Effective as of the Vivarium Commencement Date as to the Vivarium and the Expansion Commencement Date as to the Remainder Space, Sublessee will
be responsible for all janitorial services and utility costs for the applicable portion of the Expansion Space pursuant to Section 6(D) of the Original Sublease. 

8. Termination Option. Provided Sublessee fully and completely satisfies each of the conditions set forth in this Section 8,
Sublessee shall have the one time option (“Termination Option”) to terminate the Sublease as to the Expansion Space only (i.e., this Termination Option will not apply to the Existing Premises) effective as of December 31, 2021
(the “Termination Date”). In order to exercise the Termination Option, Sublessee must fully and completely satisfy each and every one of the following conditions: (a) Sublessee must give Sublessor written notice
(“Termination Notice”) on or before December 31, 2020, (b) at the time of the Termination Notice Sublessee shall not be in default under the Sublease, nor shall any circumstance exist that, with the giving of notice, the
passage of time, or both, would constitute a default under the Sublease beyond any applicable notice and cure period, (c) at the time of the Termination Notice and, at Sublessor’s option, as of the Termination Date, the Sublease shall not
have been assigned nor shall the Premises have been further sublet (unless any further sublease contains an express provision terminating such sublease prior to the Termination Date and Sublessee delivers the Expansion Space to Sublessor on the
Termination Date free from any occupancy or right of occupancy by third parties claiming through Sublessee), and (d) concurrently with Sublessee’s delivery of the Termination Notice to Sublessor, Sublessee shall pay to Sublessor a
termination fee (“Termination Fee”) equal to Six Hundred Thousand Dollars ($600,000.00). If Sublessee fails to satisfy any of the foregoing conditions, the exercise of the Termination Option will be null and void at the option of
Sublessor. 
 9. Hazardous Materials. Sublessor will provide a Surrender Plan (as defined in Article 28 of the Master Lease) to
Sublessee for the Expansion Space, which plan Sublessor will endeavor to deliver on or before October 31, 2018 (provided that the Surrender Plan as to the Vivarium will be delivered prior to the Target Delivery Date). 

10. Sublessee Improvements. Sublessee will not make any improvements or alterations to the Expansion Space without Sublessor’s
prior written consent (and the consent of Lessor if required by the Master Lease), which consent may be withheld in its reasonable discretion (provided that it shall be reasonable for Sublessor to withhold consent if Lessor withholds its consent to
such alterations or requires that such alterations be removed and the Premises be 

  
 -4- 

 restored upon lease expiration). Notwithstanding the foregoing, Sublessor consents to the removal of four
(4) private interior offices within the Expansion Space as shown on Exhibit A; provided that such consent is contingent upon Sublessee obtaining the consent of Lessor pursuant to the Master Lease) All improvements or alterations will be made in
accordance with Section 12 of the Master Lease. Sublessee shall pay any and all costs associated with such improvements or alterations. Sublessee shall be responsible for performing and completing the improvements or alterations and upon
substantial completion thereof, Sublessee shall provide to Sublessor (i) paid invoices for all of the improvements or alterations performed, (ii) a statement by the architect or contractor that all improvements or alterations have been
completed in accordance with the plans approved by Sublessor and Lessor, (iii) mechanics lien releases satisfying the requirements of California law and (iv) any other documentation reasonably requested by Sublessor or Lessor. Sublessee
shall pay Sublessor a total fee of two percent (2%) of the cost of the improvements or alterations for Lessor’s and Sublessor’s role in managing or reviewing any improvements or alterations and there shall be no additional management
fee/charges due from Sublessee related to improvements or alterations, unless Lessor charges any additional fee on account of the improvements or alterations, in which case Sublessee will reimburse such charges to Sublessor. The design and
construction of the improvements or alterations shall be subject to Sublessor’s reasonable approval and Lessor’s approval per the Master Lease and will be constructed in accordance with all terms and conditions of the Master Lease and all
applicable laws, ordinances, rules and regulations applicable to the Expansion Space. Sublessee shall use DGA Architects and DPR Construction for the space planning and construction of the improvements or alterations; provided that Lessor approves
such parties. All other subcontractors and vendors used by Sublessee will be subject to the prior consent of Sublessor and Lessor. Sublessor shall use reasonable efforts to assist Sublessee in obtaining Lessor’s approval for the improvements or
alterations, at no cost to Sublessor, but Sublessor will have no liability and this Amendment will not be affected in the event Lessor refuses to consent to any or all of Sublessee’s proposed improvements or alterations. 

At the expiration of the Expansion Space Term, Sublessee may (to the extent permitted by the Master Lease) and shall (if required by Lessor or
Sublessor) remove from the Expansion Space all improvements or alterations (and any Alterations subsequently installed by or on behalf of Sublessee) and Sublessee’s personal property and shall repair any damage and perform any restoration work
caused by such removal and shall otherwise comply with the Master Lease requirements for restoration of the Expansion Space. 
 11.
Security Deposit; First Month Rent. Sublessee has previously deposited with Sublessor Four Hundred Twenty-Four Thousand Six Hundred Forty-Four and 28/100 Dollars ($424,644.28) as a Security Deposit under the Sublease. Concurrently with
Sublessee’s execution of this Amendment, Sublessee shall deposit with Sublessor an additional One Hundred Thirty-One Thousand Five Hundred Seventy-Two and 48/100
Dollars ($131,572.48), for a total Security Deposit under the Sublease, as amended herein, of Five Hundred Fifty-Six Thousand Two Hundred Sixteen and 48/100 Dollars ($556,216.76). Sublessor shall continue to
hold the Security Deposit as increased herein in accordance with the terms and conditions of Section 17 of the Original Sublease. In addition, concurrently with Sublessee’s execution of this Amendment, Sublessee shall pay to Sublessor the
first monthly installment of Base Rent for the entire Expansion Space in the amount of $117,023.60. 

  
 -5- 

 12. Renewal Option. So long as Sublessee is not in default after any applicable
notice and cure period and has not been in default after any applicable notice and cure period under the Sublease on more than two (2) occasions during the Expansion Space Term, Sublessee physically occupies the entire Expansion Space, and
Sublessee has not assigned or further sublet the Expansion Space (except in the event of a Permitted Assignment under the Master Lease which has been consented to by Lessor to the extent required by the Master Lease), then subject to the terms of
the Master Lease and the receipt of any consent required from Lessor, Sublessee shall have one (1) option to extend the Expansion Space Term as to the Expansion Space only through the expiration date of the Original Sublease as to the Existing
Premises (i.e., through January 31, 2025) at a Base Rent equal to three percent (3%) over the Base Rent payable immediately preceding the commencement of such option term (which Base Rent will thereafter increase on each anniversary of the
commencement date of such option term by three percent (3%)). The option contained in this Section 12 shall be exercised by Sublessee, if at all, only by delivery of written notice (“Option Notice”) to Sublessor no later than
nine (9) months prior to the expiration of the Expansion Space Term, stating that Sublessee is exercising its option. If Sublessee timely and properly exercises its option to extend, the Expansion Space Term shall be extended upon all of the
terms and conditions set forth in the Sublease, as amended, except that the Base Rent for the Expansion Space shall be as indicated above. The exercise of this option is expressly contingent upon the receipt of Lessor’s consent to the extension
of the Expansion Space Term pursuant to the terms of the Master Lease. 
 a. If and only if Sublessee exercises its option to extend the
Expansion Space Term as set forth above, then Sublessee shall have the further option to extend the Expansion Space Term pursuant to Section 14 of the Original Sublease as part of Sublessee’s exercise of the option to extend the Term of
the Sublease through the date of expiration of the Master Lease. All terms and conditions set forth in Section 14 of the Original Sublease will apply to the exercise of such option, and the exercise of such option will extend the Term as to the
entire Premises. 
 b. Except for the options specifically set forth above, nothing herein shall be construed as permitting Sublessee to
exercise any extension or renewal rights or to exercise any right of first refusal or expansion, if any such rights exist, and in no event shall Sublessor be obligated to extend the term of the Master Lease for any reason. In addition,
notwithstanding anything to the contrary in the Sublease, in the event the Master Lease allows Sublessor the option to terminate the Master Lease early, Sublessor’s exercise of that option shall not be a default under the Sublease, as amended
herein. 
 13. Repair and Maintenance. Effective as of the Expansion Commencement Date, Sublessee will be responsible for all repairs
and maintenance which Tenant is required to perform in the Expansion Space and the Existing Premises, which unless the Vivarium is excluded from Premises per Section 3 above shall be the entire Master Premises under the Master Lease, and any
other repairs and maintenance of systems and equipment serving the Premises previously performed by Sublessor (including, without limitation, to the generator and deionized water system, as applicable) except for systems and equipment exclusively
serving the Vivarium if it is excluded from the Premises per Section 3 above, and Sublessor shall have no obligation to perform or pay for any repairs or maintenance in the Premises (provided that Sublessor will have the right to perform any
repairs or maintenance which Sublessee fails to perform, the cost of which will be reimbursed by Sublessee to Sublessor upon invoicing as Additional Rent). 

  
 -6- 

 14. CASp Disclosure. Pursuant to California Civil Code §1938, Sublessor hereby
states that the Premises have not undergone inspection by a Certified Access Specialist (CASp) (defined in California Civil Code §55.52(a)(3)). Pursuant to Section 1938 of the California Civil Code, Sublessor hereby provides the following
notification to Sublessee: “A Certified Access Specialist (CASp) can inspect the subject premises and determine whether the subject premises comply with all of the applicable construction-related accessibility standards under state law.
Although state law does not require a CASp inspection of the subject premises, the commercial property owner or lessor may not prohibit the lessee or tenant from obtaining a CASp inspection of the subject premises for the occupancy or potential
occupancy of the lessee or tenant, if requested by the lessee or tenant. The parties shall mutually agree on the arrangements for the time and manner of the CASp inspection, the payment of the fee for the CASp inspection, and the cost of making any
repairs necessary to correct violations of construction related accessibility standards within the premises. In the event Sublessee wishes to obtain a CASp inspection, Sublessee will be required to comply with all terms of the Master Lease and will
be responsible for the payment of all costs associated with such inspection and any cost required to correct violations of construction related accessibility standards identified by the CASp inspection. 

15. Brokers. Each party represents and warrants to the other that no broker, agent or finder negotiated or was instrumental in
negotiating or consummating this Amendment, other than Jones Lang LaSalle (for Sublessor) and Hughes Marino (for Sublessee). Each party further agrees to defend, indemnify and hold harmless the other party from and against any claim for commission
or finder’s fee by any person or entity who claims or alleges that they were retained or engaged by the indemnifying party or at the request of such party in connection with this Amendment. 

16. Lessor Consent. This Amendment is subject to and contingent upon Lessor’s execution of a consent document in a form reasonably
acceptable to Sublessor and Sublessee within thirty (30) days of the date hereof. In the event Lessor does not execute such consent within such time, either party may terminate this Amendment (in which case the Original Sublease will remain in
full force and effect notwithstanding such termination) upon written notice to the other party, which termination will be effective upon receipt. If this Amendment is terminated pursuant to this Section 16, Sublessor shall return to Sublessee
the increased portion of the Security Deposit and the first month’s rent for the Expansion Space if previously paid by Sublessee to Sublessor within fifteen (15) business days after the termination date, and neither party shall have any
liability to the other on account of this Amendment or any other actions between the parties prior to the termination date. For clarity, in the event of a termination, Sublessee will not be entitled to any reimbursement for costs or expenses
incurred by Sublessee, including without limitation, costs incurred for space planning, ordering of furniture, materials or similar items in preparation for occupancy of the Expansion Space, and Sublessee agrees that Sublessor shall have no
liability or responsibility in connection therewith. 
 17. Representations. Each party represents and warrants to the other that:
(a) it is properly formed and validly existing under the laws of the state in which it is formed and with respect to Sublessee only, is authorized to transact business in the state in which the Building is located; (b) it has full right
and authority to enter into this Amendment and to perform all of its obligations hereunder (subject to Lessor’s consent); and (c) each person (and both persons if more than one signs) signing this Amendment on behalf of such party is duly
and validly authorized to do so. 

  
 -7- 

 18. Anti-Terrorism Laws. Sublessee and Sublessor each represent and warrant that the
representing party: (i) is not, and shall not become, a person or entity with whom the other party is restricted from doing business with under regulations of the Office of Foreign Asset Control (“OFAC”) of the Department of
the Treasury (including, but not limited to, those named on OFAC’s Specially Designated and Blocked Persons list) or under any statute, executive order (including, but no limited to, the September 24, 2001 Executive Order Blocking Property
and Prohibiting Transactions with Persons Who Commit, Threaten to Commit, or Support Terrorism), or other governmental action; (ii) is not knowingly engaged in, and shall not engage in, any dealings or transaction or be otherwise associated
with such persons or entities described in (i) above; and (iii) is not, and shall not become, a person or entity whose activities are regulated by the International Money Laundering Abatement and Financial Anti-Terrorism Act of 2001 or the
regulations or orders thereunder. Prior to any change in ownership of Sublessee, the applicable party shall sign a written statement to Sublessor affirming their compliance with the terms of this Section 18. The indemnity obligations of the
Sublease shall apply to any breach of this Section. 
 19. Defaults. Sublessee hereby represents and warrants to Sublessor that, as
of the date of this Amendment, Sublessee is in full compliance with all terms, covenants and conditions of the Sublease and that there are no breaches or defaults under the Sublease by Sublessor or Sublessee, and that Sublessee knows of no events or
circumstances which, given the passage of time, would constitute a default under the Sublease by either Sublessor or Sublessee. Sublessor hereby warrants and represents to Sublessee that, to Sublessor’s current actual knowledge, the Master
Lease is in full force and effect and Sublessor has no knowledge of any claim by Lessor that Sublessor is in default or breach of any provisions of the Master Lease. 

20. No Further Modification. Except as set forth in this Amendment, all of the terms and provisions of the Sublease shall apply with
respect to the Expansion Space and shall remain unmodified and in full force and effect. Effective as of the date hereof, all references to the “Sublease” shall refer to the Sublease as amended by this Amendment. 

21. Counterparts. This Amendment may be executed in any number of counterparts, which may be delivered electronically, via facsimile or
by other means. Each party may rely upon signatures delivered electronically or via facsimile as if such signatures were originals. Each counterpart of this Amendment shall be deemed to be an original, and all such counterparts (including those
delivered electronically or via facsimile), when taken together, shall be deemed to constitute one and the same instrument. 
 [Signature
Page Follows] 

  
 -8- 

 IN WITNESS WHEREOF, this Amendment has been executed as of the day and year first above
written. 
 “Sublessor:” 

 

			
	 THE MEDICINES COMPANY,
 a Delaware
corporation

		
	By:	 	/s/ Christopher Visioli
		 	 Print Name: Christopher Visioli 

Title: Chief Financial Officer 

 “Sublessee” 

 

			
	 GOSSAMER BIO, INC.,
 a Delaware
corporation

		
	By:	 	/s/ Christian Waage
		 	 Print Name: Christian Waage
 Title:
Executive Vice President & General
Counsel

  
 -9-EX-10.17

 Exhibit 10.17 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT (INDICATED BY ASTERISKS) HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. 
 EXECUTION COPY 

EXCLUSIVE LICENSE AGREEMENT 

by and between 
 FSG
Pulmo, Inc., 
 FSG Bio, Inc., 

and 
 Pulmokine, Inc.

 Dated as of the 2nd day of October, 2017 

 Table of Contents 

							
	 1. DEFINITIONS
	  	 	1	 
	 1.1.
	 	Definitions.	  	 	1	 
	 1.2.
	 	Additional Definitions.	  	 	8	 
	 1.3.
	 	Rules of Construction.	  	 	10	 
		
	 2. GRANT OF LICENSE; OTHER RIGHTS
	  	 	10	 
	 2.1.
	 	Licenses to Licensee Under Licensed Technology; Sublicenses.	  	 	10	 
	 2.2.
	 	Gilead and RCTR Licenses.	  	 	11	 
	 2.3.
	 	Use of Affiliates and Third Party Contractors.	  	 	11	 
	 2.4.
	 	Registration and Recordation of Licenses.	  	 	11	 
	 2.5.
	 	No Implied Licenses; Retained Rights.	  	 	12	 
	 2.6.
	 	Exclusivity.	  	 	12	 
	 2.7.
	 	Field Expansion Option.	  	 	12	 
		
	 3. CONSIDERATION
	  	 	13	 
	 3.1.
	 	Up-front Closing and Field Expansion Payment.	  	 	13	 
	 3.2.
	 	Development Milestones.	  	 	13	 
	 3.3.
	 	Regulatory Milestones.	  	 	14	 
	 3.4.
	 	Sales Milestones.	  	 	15	 
	 3.5.
	 	Royalty.	  	 	15	 
	 3.6.
	 	Sublicensing Income and Purchaser Income.	  	 	16	 
	 3.7.
	 	Royalty Payment Timing; Reports of Net Sales.	  	 	16	 
	 3.8.
	 	Audits.	  	 	17	 
	 3.9.
	 	Currency.	  	 	17	 
	 3.10.
	 	Account.	  	 	17	 
	 3.11.
	 	Taxes.	  	 	18	 
	 3.12.
	 	Interest on Late Payments.	  	 	18	 
	 3.13.
	 	Permitted Reductions.	  	 	18	 
	 3.14.
	 	FSG Guaranty.	  	 	19	 
		
	 4. DEVELOPMENT AND COMMERCIALIZATION OF LICENSED PRODUCTS
	  	 	19	 
	 4.1.
	 	Know-How and Regulatory Filings.	  	 	19	 
	 4.2.
	 	General.	  	 	19	 
	 4.3.
	 	Regulatory.	  	 	20	 
	 4.4.
	 	Reporting.	  	 	20	 
	 4.5.
	 	Supply of Licensed Product.	  	 	20	 
	 4.6.
	 	Technology Transfer.	  	 	20	 
		
	 5. JOINT DEVELOPMENT COMMITTEE
	  	 	21	 
	 5.1.
	 	Formation; Composition.	  	 	21	 
	 5.2.
	 	Responsibilities.	  	 	21	 
	 5.3.
	 	Decision-Making.	  	 	21	 
	 5.4.
	 	Meetings.	  	 	21	 
	 5.5.
	 	Meeting Agenda; Minutes.	  	 	22	 
	 5.6.
	 	Dissolution on Change of Control.	  	 	22	 
		
	 6. INTELLECTUAL PROPERTY
	  	 	22	 
	 6.1.
	 	Patent Prosecution and Maintenance.	  	 	22	 
	 6.2.
	 	Enforcement of Intellectual Property Rights.	  	 	22	 

  

							
	 6.3.
	 	Third Party Actions.	  	 	23	 
	 6.4.
	 	Ownership of Inventions.	  	 	23	 
	 6.5.
	 	Patent Cooperation.	  	 	24	 
	 6.6.
	 	Orange Book.	  	 	24	 
	 6.7.
	 	Patent Term Extensions.	  	 	25	 
	 7. REPRESENTATIONS, WARRANTIES AND COVENANTS
	  	 	25	 
	 7.1.
	 	No Litigation.	  	 	25	 
	 7.2.
	 	No Debarment.	  	 	25	 
	 7.3.
	 	Corporate Existence.	  	 	25	 
	 7.4.
	 	Authority to Execute and Perform.	  	 	25	 
	 7.5.
	 	Non-Contravention.	  	 	26	 
	 7.6.
	 	Additional Pulmokine Representations, Warranties and Covenants.	  	 	26	 
	 7.7.
	 	No Implied Warranties.	  	 	27	 
		
	 8. CONFIDENTIALITY OBLIGATIONS OF PULMOKINE
	  	 	27	 
	 8.1.
	 	Confidentiality Obligations.	  	 	27	 
	 8.2.
	 	Exceptions.	  	 	28	 
		
	 9. CONFIDENTIALITY OBLIGATIONS OF LICENSEE
	  	 	29	 
	 9.1.
	 	Confidentiality Obligations.	  	 	29	 
	 9.2.
	 	Exceptions.	  	 	29	 
	 9.3.
	 	Additional Disclosure.	  	 	30	 
		
	 10. SCIENTIFIC PUBLICATIONS
	  	 	30	 
		
	 11. PRESS RELEASES
	  	 	30	 
	 11.1.
	 	Joint Press Release.	  	 	30	 
	 11.2.
	 	No Disclosure of Terms and Conditions.	  	 	31	 
		
	 12. INDEMNIFICATION AND INSURANCE
	  	 	31	 
	 12.1.
	 	By Licensee.	  	 	31	 
	 12.2.
	 	By Pulmokine.	  	 	31	 
	 12.3.
	 	Indemnification Procedure.	  	 	32	 
	 12.4.
	 	Insurance.	  	 	33	 
		
	 13. LIMITATION ON LIABILITY
	  	 	33	 
		
	 14. TERM
	  	 	34	 
		
	 15. TERMINATION; EFFECT OF TERMINATION
	  	 	34	 
	 15.1.
	 	Termination for Convenience	  	 	34	 
	 15.2.
	 	Termination for Safety or Efficacy.	  	 	34	 
	 15.3.
	 	Material Breach.	  	 	34	 
	 15.4.
	 	Patent Challenge.	  	 	34	 
	 15.5.
	 	Force Majeure.	  	 	35	 
	 15.6.
	 	Insolvency.	  	 	35	 
	 15.7.
	 	Rights Upon Certain Termination Events.	  	 	35	 
	 15.8.
	 	Return of Confidential Information.	  	 	36	 
	 15.9.
	 	Survival.	  	 	36	 
	 15.10.
	 	Other Remedies.	  	 	36	 
	 15.11.
	 	Bankruptcy Code.	  	 	36	 

  
 ii 

							
	 16. GENERAL PROVISIONS
	  	 	36	 
	 16.1.
	 	Assignment.	  	 	36	 
	 16.2.
	 	Right to Set-Off.	  	 	37	 
	 16.3.
	 	Force Majeure.	  	 	37	 
	 16.4.
	 	Governing Law.	  	 	37	 
	 16.5.
	 	Dispute Resolution.	  	 	37	 
	 16.6.
	 	Compliance with Laws.	  	 	39	 
	 16.7.
	 	Headings.	  	 	39	 
	 16.8.
	 	Waiver.	  	 	39	 
	 16.9.
	 	Notices.	  	 	39	 
	 16.10.
	 	Severability.	  	 	40	 
	 16.11.
	 	Entire Agreement.	  	 	40	 
	 16.12.
	 	Amendment.	  	 	40	 
	 16.13.
	 	Counterparts.	  	 	40	 
	 16.14.
	 	Agency.	  	 	41	 
	 16.15.
	 	Further Assurances.	  	 	41	 

 EXHIBITS: 

Exhibit A – Backup Compound 

Exhibit B – Compound 

Exhibit C – Gilead Background Patents 

Exhibit D – Phase 1 Clinical Trial Plan 

Exhibit E – Pulmokine-Controlled Patents 

Exhibit F – Pulmokine-Gilead Joint Patents 

Exhibit G – Asthma Compounds 

Exhibit H – Biomarker Patents 

Exhibit I – RCTR License Terms 

  
 iii 

 EXCLUSIVE LICENSE AGREEMENT 

This Exclusive License Agreement is entered into as of the 2nd day of October, 2017, by
and between FSG Pulmo, Inc., a corporation organized under the laws of the State of Delaware having its registered office at 17 Selborne Drive, Piedmont, CA 94611 USA (“Licensee”), Pulmokine, Inc., a corporation organized under the
laws of the State of Delaware having its registered office at 68 Queen Anne Drive, Slingerlands, New York 12159 (“Pulmokine”), and solely with respect to Section 3.14, FSG Bio, Inc., a corporation organized under the laws of
the State of Delaware having its registered office at 17 Selborne Drive, Piedmont, CA 94611 USA (“FSG”). Licensee and Pulmokine are also referred to individually as a “Party” and together as the
“Parties.” 
 BACKGROUND: 

WHEREAS, Pulmokine has in-licensed from Gilead Sciences, Inc. (“Gilead”) and
developed certain intellectual property rights related to numerous compounds, including an inhaled small molecule PDGFR (platelet-derived growth factor receptor) kinase inhibitor known as PK10571 and its active metabolite known as PK10453, which are
included in the Licensed Patents and Licensed Know-How (each as defined herein); 
 WHEREAS,
Pulmokine has in-licensed from The Rensselaer Center for Translational Research, Inc. (“RCTR”) and developed certain intellectual property rights related to certain biomarkers intended to
diagnose pulmonary arterial hypertension, which are included in the Licensed Patents and Licensed Know-How; 

WHEREAS, Licensee is an Affiliate of FSG; and 

WHEREAS, Licensee desires to obtain from Pulmokine an exclusive license under the Licensed Patents and an exclusive license under the
Licensed Know-How to further develop and commercialize products based on such molecules in certain fields in the Territory (as defined below), and Pulmokine desires to grant such licenses to Licensee, together
with certain other rights. 
 AGREEMENT: 

NOW, THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows: 
 1. DEFINITIONS 

1.1. Definitions. 
 The
following terms as used in this Agreement shall have the meanings set forth in this Section: 
 “Affiliate” means, with
respect to each Party, any Person that directly or indirectly is controlled by, controls or is under common control with a Party. For the purposes of this definition only, the term “control” (including, with correlative meanings, the terms
“controlled by” and “under common control with”) as used with respect to a Person means (a) in the case of a corporate entity, direct or indirect ownership of voting securities entitled to cast at least fifty percent (50%)
of the votes in the election of directors or (b) in the case of a non-corporate entity, direct or indirect ownership of at least fifty percent (50%) of the equity interests with the power to direct the
management and policies of such entity; provided that, if local Laws restrict foreign ownership, control shall be established by direct or indirect ownership of 

 
the maximum ownership percentage that may, under such local Laws, be owned by foreign interests, but only if such lower percentage provides such Person with the power to direct the management and
policies of such entity. 
 “Agreement” means this Exclusive License Agreement, including all of its Exhibits. 

“Asthma Compounds” means (a) the PDGFR kinase inhibitor compounds having the structures identified in Exhibit G;
(b) any compound [***] to the extent not set forth in subsection (a); and (c) any [***] set forth in subsections (a) or (b). 

“Asthma Patents” means (a) those patents and patent applications set forth on Exhibit G; (b) any patents and
patent applications in any country claiming priority to any and all of the patent applications set forth in (a), including any continuations, continuations in part, or divisions; (c) any patents issuing from the applications described in
subsections (a) or (b), including any reissues, substitutions, registrations, confirmations, re-examinations, extensions, renewals, and supplementary protection certificates thereon; and (d) any
corresponding foreign patents issued on any of the foregoing. 
 “Backup Compound” means (a) the [***], having the
structure identified in Exhibit A and (b) [***] set forth in subsection (a). 
 “Biomarkers” means the biomarker and
methods relating thereto that are the subject of the Biomarker Patents. 
 “Biomarker Patents” means (a) the patent
applications listed in Exhibit H, all divisions and continuations of these applications in any country, all patents issuing from these applications, divisions, and continuations, and any reissues, reexaminations, and extensions of these
patents; (b) to the extent that the following contain one or more claims directed to the invention or inventions disclosed in the patent applications identified in subsection (a): (i) continuations-in-part of those patent applications identified in subsection (a), (ii) all divisions and continuations of these
continuations-in-part, (iii) all patents issuing from these continuations-in-part,
divisions, and continuations, (iv) priority patent application(s) of such patent applications identified in subsection (a), and (v) any reissues, reexaminations, and extensions of such patents; and (c) to the extent that the following
contain one or more claims directed to the invention or inventions disclosed in the patent applications identified in subsection (a): all counterpart foreign and U.S. patent applications and patents to those patent applications and patents
identified in subsections (a) and (b), including those listed in Exhibit H. The Biomarker Patents shall not include those patent applications or patents identified in subsection (b) or (c) hereof, to the extent that they contain one
or more claims directed to new matter which is not the subject matter disclosed in the patent applications identified in subsection (a). 

“Business Day” means a day other than Saturday, Sunday or any day on which commercial banks located in New York City, New
York are authorized or obligated by Law to close. 
 “Calendar Quarter” means any consecutive three (3)-month period
beginning on January 1, April 1, July 1 or October 1. 
 “Calendar Year” means any year beginning on
January 1 and ending on December 31 of such year. 
  

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  
 2 

 “Change of Control” shall mean with respect to a Party, the merger,
consolidation, reorganization, business combination, sale of all (or substantially all) of the capital stock (or other equity interests) or assets, the change in voting control, liquidation or dissolution, the license, sale, assignment or other
transfer of all or substantially all of such Party’s business or assets to which this Agreement relates, or any other form of acquisition or liquidity event. For clarity, a Change of Control of any parent of Licensee shall not be a Change of
Control of Licensee for purposes of this Agreement. 
 “Commercially Reasonable Efforts” means, with respect to the efforts
and resources to be expended, or considerations to be undertaken by a Party with respect to any objective, activity, or decision to be undertaken hereunder, the use of reasonable, good faith efforts and resources in an active and ongoing program to
accomplish such task or obligation [***]. 
 “Complete” or “Completion” means, with respect to the Phase 1
Clinical Trial for the initial Licensed Product, finalization of the study report. 
 “Compound” means (a) the small
molecule PDGFR kinase inhibitor known as of the Effective Date as [***], having the structure identified in Exhibit B, and (b) [***]of the small molecule PDGFR kinase inhibitor set forth in subsection (a), [***]. 

“Confidential Information” means Licensee Confidential Information or Pulmokine Confidential Information. 

“Confidentiality Agreement” means the Confidentiality Agreement between the Parties dated May 21, 2017. 

“Control” or “Controlled” means, with respect to any Data, Information or Scientific Information, materials,
patent, trademark or other intellectual property right, possession of the ability to grant a license, sublicense or access as provided for under this Agreement without violating the terms of any agreement or other arrangement with any Third Party.

 “Cover”, “Covered” or “Covering” means, with respect to a particular product and a particular
patent (or patent application), that, but for rights granted to a Person hereunder, the making, using or selling of such product would infringe a Valid Claim in such patent (or patent application, as if such claim has issued). 

“Data” means any and all research, pharmacology, medicinal chemistry, chemistry, manufacturing and controls, nonclinical,
clinical and other data (including investigator reports and clinical study reports (both preliminary and final), statistical analyses, key expert reports, safety and other electronic databases), all to the extent Controlled by a Party, in each case,
relating to the Compound, Backup Compound, Asthma Compound, Biomarkers or Licensed Products. 
 “Effective Date” means the
later of: (a) the date set forth above in the first line of this Agreement; and (b) the date of Licensee’s receipt of the Up-front Closing Payment. 

“EMA” means the European Medicines Agency or any successor entity thereto. 

 

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  
 3 

 “European Union” or “EU” means the association of European
nations based on the Maastrict Treaty of 1992. 
 “FDA” means the United States Food and Drug Administration or any
successor entity thereto. 
 “FDCA Act” means the U.S. Federal Food, Drug, and Cosmetic Act, as amended from time to time,
and the regulations promulgated thereunder. 
 “First Commercial Sale” means, with respect to any particular Licensed
Product, the first arm’s length commercial sale of such Licensed Product by Licensee or an Affiliate or Sublicensee of Licensee to a Third Party in the Licensed Product Field in the Territory following Regulatory Approval of such Licensed
Product. 
 “GAAP” means Generally Accepted Accounting Principles, consistently applied. 

“GCP” means then current good clinical practices and other standards, practices and procedures related to the conduct of
clinical trials set forth by ICH and similar regulatory requirements imposed by FDA, EMA or any other Regulatory Authorities in the Territory that are applicable to the Licensed Product. 

“Gilead Background Patents” means (a) those patents and patent applications set forth on Exhibit C; (b) any
patents and patent applications in any country claiming priority to any and all of the patent applications set forth in (a), including any continuations, continuations in part, or divisions; (c) any patents issuing from the applications
described in (a) or (b), including any reissues, substitutions, registrations, confirmations, re-examinations, extensions, renewals, and supplementary protection certificates thereon; and (d) any
corresponding foreign patents issued on any of the foregoing. 
 “Gilead License” means that certain Amended and Restated
License Agreement between Gilead and Pulmokine dated May 15, 2017. 
 “ICH” means the International Conference on
Harmonisation. 
 “IND” means an Investigational New Drug filing with FDA, as defined in the FDCA Act, including all
supplements and amendments thereto. 
 “Improvement” means any patentable or unpatentable improvements, changes, inventions
or discoveries, inclusive of all intellectual property rights therein, in which one or more employees, officers, directors, contractors or agents of Licensee, its Affiliates or Sublicensees (or as applicable together with one or more employees,
officers, directors, contractors or agents of Pulmokine) have contributed to the making, development, conception and/or reduction to practice of such improvement, change, invention or discovery, and that (a) is described in the Licensed
Patents, or (b) if not for the license granted pursuant to Section 2.1 of this Agreement, would infringe one or more claims of the Licensed Patents. 

“Information” means all information, Data, techniques, technology, practices, trade secrets, inventions (whether patentable
or not), methods, knowledge, know-how, skill, experience, test data and results (including pharmacological, toxicological and clinical test data and results), analytical and quality control data, results or
descriptions, software and algorithms, all to the extent Controlled by a Party. 
 “Joint Development Committee” or
“JDC” means the committee formed by the Parties pursuant to Section 5.1. 

  
 4 

 “Law” means all applicable laws, statutes, rules, regulations, ordinances
and other pronouncements having the effect of law of any federal, national, multinational, state, provincial, county, city or other political subdivision, agency or other body, domestic or foreign, and including without limitation the FDCA Act and
GCP, as applicable. 
 “Licensed Know-How” means Information, Data and Scientific
Information owned or Controlled by Pulmokine as of the Effective Date [***] of the Licensed Products.  

“Licensed Patents” means, collectively, the Gilead Background Patents, Pulmokine-Gilead Joint Patents, Pulmokine-Controlled
Patents, Asthma Patents, and the Biomarker Patents. 
 “Licensed Product” means (a) any pharmaceutical composition,
formulation or product containing or incorporating the Compound, whether or not as the sole active ingredient, in any presentation for any method of administration; (b) any pharmaceutical composition, formulation or product containing or
incorporating the Backup Compound, whether or not as the sole active ingredient, in any presentation for any method of administration; (c) any pharmaceutical composition, formulation or product containing or incorporating the Asthma Compound,
whether or not as the sole active ingredient, in any presentation for any method of administration; (d) any process, assay or tangible material, which, in the course of being practiced, manufactured, used, sold or imported, would contain or
otherwise incorporate one or more of the Biomarkers or other subject matter that is the subject of the Biomarker Patents; and/or (e) any pharmaceutical composition, formulation or product containing or incorporating any compound Covered by the
Gilead Background Patents, Pulmokine-Gilead Joint Patents, Pulmokine-Controlled Patents, including the Asthma Compounds but excluding the Compound and the Backup Compound, whether or not as the sole active ingredient, in any presentation for any
method of administration. 
 “Licensed Product Field” means (a) with respect to any Licensed Product that incorporates
[***], the treatment, prevention, and diagnosis of pulmonary hypertension characterized as [***]; (b) with respect to any Licensed Product that [***], the treatment, prevention, and diagnosis of any and all diseases or conditions; and (c) with
respect to any License Product that [***], for the treatment, prevention, and diagnosis of any and all diseases or conditions. 

“Licensed Technology” means, collectively, the Licensed Patents and the Licensed
Know-How. 
 “Marketing Exclusivity” means any exclusive marketing, data protection
or other exclusivity rights conferred by FDA, EMA or any other Regulatory Authority with respect to the Licensed Product, including orphan drug exclusivity, pediatric exclusivity and rights conferred under the Drug Price Competition and Patent Term
Restoration Act of 1984, as amended from time to time. 
 “NDA” means a New Drug Application, as defined in the FDCA Act,
including all supplements and amendments thereto. 
 “Net Sales” means the gross invoiced sales price for each Licensed
Product sold by or on behalf of Licensee, its Affiliates or Sublicensees to Third Parties, less the following deductions calculated in accordance with GAAP to the extent allocated to such Licensed Product and actually taken, paid, accrued, allowed,
included, or allocated, with respect to such sales: 
 (a) [***]; 

(b) [***]; 
 (c) [***]; 

(d) [***]; 
 (e) [***]; 

(f) [***]; and 
 (g) [***]. 

Notwithstanding anything in this Agreement to the contrary, the transfer of a Licensed Product between or among Licensee, its Affiliates and
Sublicensees will not be considered a sale, [***]. 
 Disposition of Licensed Product for, or use of the Licensed Product in, human clinical
trials or other scientific testing, as free samples, or under named patient use, compassionate use, patient assistance, 
  

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  
 5 

 
or test marketing programs or other similar programs or studies shall not result in any Net Sales when such sales are not booked as Net Sales in accordance with GAAP. 

[***] 
 (x) [***]; or 

(y) [***]. 

“Person” means any individual, firm, corporation, partnership, limited liability company, trust, business trust, joint
venture, governmental authority, association or other entity. 
 “Phase 1 Clinical Trial” means a human clinical trial of a
Licensed Product that would satisfy the requirements of 21 C.F.R. § 312.21(a) and consists of the Phase 1A clinical trial to be performed by Pulmokine and its subcontractors as described in Pulmokine’s IND 122593 and consists of the
first in human exposure in healthy subjects. 
 “Phase 1 Clinical Trial Plan” means the clinical trial plan and protocol
for the Phase 1 Clinical Trial of the initial Licensed Product attached as described in Pulmokine’s IND 122593 and attached hereto as Exhibit D which satisfies the requirements of 21 CFR § 312.21 (a), and which may be amended
from time to time during the performance thereof, as agreed by the principal investigator of the applicable contract research organization and the JDC. 

“Phase 1B Clinical Trial” means the first safety trial in patients with pulmonary arterial hypertension (PAH) of the initial
License Product that would also satisfy the requirements of 21 CFR § 312.21(a). 
 “Phase 2 Clinical Trial” means
a human clinical trial of a Licensed Product that would satisfy the requirements of 21 C.F.R. § 312.21(b), and which may be combined with a Phase 1B Clinical Trial, such that the primary endpoint can be safety and secondary endpoints can
be efficacy endpoints. 
 “Phase 3 Clinical Trial” means a human clinical trial of a Licensed Product that would satisfy
the requirements of 21 C.F.R. § 312.21(c). For purposes of this Agreement, if acceptable to the FDA, performance of a second Phase 2 Clinical Trial, the results of which would satisfy the requirements for Regulatory Approval, will meet the
requirements of a Phase 3 Clinical Trial. 
 “Pulmokine-Controlled Patents” means (a) any patent or patent application
owned (whether solely or jointly) or Controlled by Pulmokine that Covers the Compound, the Backup Compound, or the Asthma Compound, including those patents and patent applications set forth on Exhibit E and Exhibit G; (b) any
patents and patent applications in any country claiming priority to any and all of the patent applications set forth in (a), including any continuations, continuations in part, or divisions; (c) any patents issuing from the applications
described in (a) or (b), including any reissues, substitutions, registrations, confirmations, re-examinations, extensions, renewals, and supplementary protection certificates thereon; and (d) any
corresponding foreign patents issued on any of the foregoing. For purposes of this Agreement, Pulmokine-Controlled Patents do not include Gilead Background Patents or Pulmokine-Gilead Joint Patents. 

 

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  
 6 

 “Pulmokine-Gilead Joint Patents” means (a) any patent or patent
application owned jointly by Pulmokine and Gilead that Covers the Compound or the Backup Compound, including those patents and patent applications set forth on Exhibit F; (b) any patents and patent applications in any country claiming
priority to any and all of the patent applications set forth in (a), including any continuations, continuations in part, or divisions; (c) any patents issuing from the applications described in (a) or (b), including any reissues,
substitutions, registrations, confirmations, re-examinations, extensions, renewals, and supplementary protection certificates thereon; and (d) any corresponding foreign patents issued on any of the
foregoing. 
 “RCTR License” means that certain Patent License Agreement between RCTR and Pulmokine dated September 8,
2017. 
 “Regulatory Approval” means, with respect to a country or region in the Territory, any and all approvals,
licenses, registrations or authorizations of any Regulatory Authority which are necessary to commercially distribute, sell or market a product in such country or region, including, where applicable, (a) pricing or reimbursement approval in such
country or region, (b) pre- and post-approval marketing authorizations (including without limitation any prerequisite manufacturing approval or authorization related thereto), (c) labeling approval
and (d) technical, medical and scientific licenses, necessary for commercial distribution, sale or marketing of such product in such country or region. 

“Regulatory Approval Application” means an application for Regulatory Approval required before commercial sale or use of a
pharmaceutical product, including an NDA. 
 “Regulatory Authority” means any federal, national, supranational, state,
provincial or local regulatory authority, agency, department, bureau or other governmental authority, including the FDA and EMA, that has authority over the manufacture, development, commercialization or other use or exploitation (including the
granting of Regulatory Approval) of the Licensed Product in an applicable jurisdiction. 
 “Regulatory Filing” means all
submissions, applications, filings and approvals by, with or from any Regulatory Authority, including Regulatory Approval Applications. 

“Royalty Term” means, on a Licensed
Product-by-Licensed Product and country-by-country basis, that time period beginning on
the First Commercial Sale of such Licensed Product and ending on the last to occur of: (a) expiration of the last-to-expire Valid Claim of any Licensed Patent in a
particular country that, absent the licenses granted in this Agreement, would be infringed by the making, using, selling, offering for sale, importing or exporting of the applicable Licensed Product in such country, (b) expiration of the
Marketing Exclusivity, if any, of the applicable Licensed Product in a country of the Territory; or (c) ten (10) years after the First Commercial Sale of such Licensed Product. 

“Scientific Information” means all Information relating to the Compound, Backup Compound, Asthma Compounds, Biomarkers or
Licensed Products and comprising medical, toxicological, pharmacological, pre-clinical, clinical or chemical data; specifications; medical uses; adverse reactions; formulations; bioanalytical metrics;
analytical and quality control data and methods; and all proprietary information intended for submission or submitted to relevant Regulatory Authorities to support a Regulatory Approval Application for and Regulatory Approval of the Licensed
Products in the Licensed Product Field in any country in the world, all to the extent Controlled by a Party. 
 “Second
Indication” means, with respect to a Licensed Product, an indication that is distinct from all indications covered by the Regulatory Approvals of such Licensed Product from the applicable Regulatory Authority (e.g., for the treatment
of a disease that is distinct from any disease(s) for which Regulatory Approval has been previously granted) and distinct from all variants or sub-divisions or
sub-

  
 7 

 
classifications of such indications. For clarity, the following uses shall not be considered a Second Indication: (a) the use of a Licensed Product in a line of therapy for an indication
where the initially-approved indication is the use of such Licensed Product in another line of therapy for such indication (e.g., moving from second-line therapy to first-line therapy for the treatment of pulmonary hypertension) or (b) the use
of a Licensed Product in a subset of patients (e.g., elderly, pediatric, or genetically defined patient subgroups, etc.) for an indication where the initially-approved indication is the use of such Licensed Product within another subset of patients
for such indication. 
 “Sublicensee” means a Third Party to whom Licensee has granted a license or sublicense under the
Licensed Technology, in accordance with the terms of this Agreement, to make, have made, use, sell, offer for sale, have sold, import or export a Licensed Product. 

“Territory” means all countries of the world, or worldwide. 

“Third Party” means any Person other than Licensee and Pulmokine and their respective Affiliates. 

“United States” or “U.S.” means the United States of America and its territories and possessions. 

“USD” means a United States Dollar. 

“Valid Claim” means (a) a claim of an issued and unexpired patent, which claim has not been held invalid or
unenforceable by a court or other government agency of competent jurisdiction from which no appeal can be or has been taken and has not been held or admitted to be invalid or unenforceable through
re-examination or disclaimer, opposition procedure, nullity suit or otherwise and (b) a claim of any patent application that has been pending for fewer than seven (7) years after the earliest priority
date of such patent application. 
 1.2. Additional Definitions. 

The following table identifies the location of definitions set forth in various Sections of the Agreement: 

 

			
	DEFINED TERM	  	SECTION
		
	Additional Third Party Licenses	  	Section 3.13(a)
		
	Asthma Field Expansion	  	Section 2.7(b)
		
	Background Patent Field	  	Section 1.15 of Gilead License
		
	Background Product	  	Section 1.15 of Gilead License
		
	Broad Field	  	Section 1.15 of Gilead License
		
	Combination Product	  	Definition of Net Sales

  
 8 

			
		
	Controlled Entity	  	Section 3.6
		
	Damages	  	Section 12.1
		
	Development Milestone	  	Section 3.2
		
	Dispute	  	Section 16.5(a)
		
	Equity Interest	  	Section 3.6
		
	Excluded Claim	  	Section 16.4(g)
		
	Field	  	Section 1.15 of Gilead License
		
	Field Expansion	  	Section 2.7(a)
		
	Force Majeure	  	Section 16.2
		
	FSG	  	Preamble
		
	Fully Diluted Basis	  	Section 3.6
		
	Future New Inventions	  	Section 1.16 of Gilead License
		
	Generic Product Competition	  	Section 3.13(b)
		
	Gilead	  	Background
		
	ICC Rules	  	Section 16.4(c)
		
	Indemnification Claim Notice	  	Section 12.3(a)
		
	Indemnified Party	  	Section 12.3(a)
		
	Indemnifying Party	  	Section 12.3(a)
		
	Joint Inventions	  	Section 6.4(b)
		
	Licensee	  	Preamble
		
	Licensee Confidential Information	  	Section 8.1(a)
		
	Licensee Indemnitees	  	Section 12.2
		
	Licensee Inventions	  	Section 6.4(a)
		
	Licenses	  	Section 2.1(a)
		
	Orange Book	  	Section 6.6

  
 9 

			
		
	Party or Parties	  	Preamble
		
	Patent Challenge	  	Section 15.4
		
	Practical Application	  	Section 4.2
		
	Pulmokine	  	Preamble
		
	Pulmokine Confidential Information	  	Section 9.1(a)
		
	Pulmokine Indemnitees	  	Section 12.1
		
	Regulatory Milestone	  	Section 3.3
		
	Sales Milestone	  	Section 3.4
		
	Senior Executives	  	Section 16.4(a)
		
	Term	  	Article 14
		
	Up-front Closing Payment	  	Section 3.1

 1.3. Rules of Construction. 

The definitions set forth in Section 1.1 and elsewhere in this Agreement shall apply equally to both the singular and plural forms of the
terms defined. Whenever the context may require, any pronoun shall include the corresponding masculine, feminine and neuter forms. The words “include,” “includes” and “including” shall be deemed to be followed by the
phrase “but not limited to.” The use of the words “or” and “any” shall not be exclusive except where the context indicates otherwise. All references herein to Articles, Sections and Exhibits shall be deemed references
to Articles and Sections of, and Exhibits to, this Agreement unless the context shall otherwise require. All Exhibits attached to this Agreement shall be deemed incorporated herein by reference as if fully set forth herein. Words such as
“herein,” “hereof,” “hereto,” “hereby” and “hereunder” refer to this Agreement and to the Exhibits, taken as a whole. Except as otherwise expressly provided herein: (a) any reference in this
Agreement to any agreement shall mean such agreement as amended, restated, supplemented or otherwise modified from time to time; and (b) any reference in this Agreement to any Law shall include corresponding provisions of any successor Law and
any regulations and rules promulgated pursuant to such Law or such successor Law. 
 2. GRANT OF LICENSE; OTHER RIGHTS 

2.1. Licenses to Licensee Under Licensed Technology; Sublicenses. 

(a) Subject to the terms and conditions set forth in this Agreement, Pulmokine hereby grants to Licensee: (i) an exclusive right and
license (and sub-license under the Gilead License and RCTR License), with the right to grant sublicenses through multiple tiers in accordance with this Section 2.1, under the Licensed Patents; and
(ii) an exclusive right and license, with the right to grant sublicenses in accordance with this Section 2.1, under the Licensed Know-How, in each of (i) and (ii) to research, develop,
commercialize, manufacture, make, have made, use, sell, offer for sale, have sold, import, export and 

  
 10 

 
otherwise commercially exploit Licensed Products in the Licensed Product Field in the Territory (the “Licenses”). 

(b) Licensee may grant sublicenses to its Affiliates and/or Third Parties under the Licensed Patents and Licensed Know-How without Pulmokine’s consent. Each sublicense shall be consistent with the applicable terms and conditions under this Agreement and any sublicenses granted to Third Parties shall be negotiated at
arms-length and shall be for such consideration and on such terms as Licensee believes in good faith are commercially reasonable. Licensee shall, within [***] after entering into any sublicense agreement, provide Pulmokine with a copy of such
sublicense agreement, which may be redacted to remove any sensitive information not necessary for Pulmokine to verify its compliance with the terms of this Agreement and which sensitive information, for the purposes of this Section 2.1(b),
shall [***]. Notwithstanding the foregoing, within [***] after entering into any sublicense agreement pursuant to which Licensee grants sublicenses [***], Licensee shall provide Pulmokine with a true and complete copy of such sublicense agreement,
[***] such breach or terminating such sublicense agreement. 
 2.2. Gilead and RCTR Licenses. 

(a) Licensee acknowledges and agrees that the licenses and rights are granted by Pulmokine to Licensee under: (i) the Gilead Background
Patents and the Pulmokine-Gilead Joint Patents which are licensed from Gilead pursuant to the Gilead License; and (ii) the Biomarker Patents, which are licensed from RCTR pursuant to the RCTR License and remain subject to the terms of such RCTR
License, including the terms set forth in Sections 5.1-5.4, 8.1, 10.1, 10.2, 12.5 and 13.8-13.10 of the RCTR License, which have been reproduced in Exhibit I and
shall be binding upon Licensee as if it were a party to such RCTR License. 
 (b) In the event that the Gilead License is terminated, this
Agreement shall survive in accordance with the terms of Section 9.4 of the Gilead License. 
 (c) In the event that the RCTR License is
terminated, at FSG’s option and in accordance with Section 4.3 of the RCTR License, the rights in and to the Biomarker Patents that are sublicensed to FSG in Section 2.1(a) shall be terminated or, subject to RCTR’s approval and
contingent upon FSG’s acceptance of the provisions of the RCTR License, converted to a license directly between FSG and RCTR. 

2.3. Use of Affiliates and Third Party Contractors. 

Subject at all times to Licensee’s compliance with Section 2.1(b) hereof, the Licenses granted under this Agreement include the right
of Licensee to freely engage its Affiliates and Third Party contractors in exercising such rights and in carrying out its activities and obligations under this Agreement. 

2.4. Registration and Recordation of Licenses. 

Notwithstanding anything to the contrary in Article 9, Licensee may register and/or record the Licenses granted under this Agreement in any
country in the Territory. Upon request by Licensee, Pulmokine agrees promptly to execute any “short form” licenses consistent with the terms and conditions of this Agreement submitted to it by Licensee reasonably necessary to effect the
foregoing registration in such country. 
  

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  
 11 

 2.5. No Implied Licenses; Retained Rights. 

Except as expressly set forth herein, neither Party shall acquire any license or other right or interest, by implication or otherwise, under
any Information, patents, trademarks, copyrights or any other intellectual property of the other Party or its Affiliates. Solely with respect to any Licensed Patents supported by federal funding, if any, the rights and licenses granted to Licensee
by Pulmokine hereunder are subject to the rights, conditions and limitations imposed by United States Law (see 35 U.S.C. § 202 et seq. and regulations pertaining thereto), including without limitation: (i) the royalty-free, non-exclusive license granted to the U.S. government; and (ii) the requirement that any Licensed Product used or sold in the United States shall normally be manufactured substantially in the United States. 

All rights not expressly granted by Pulmokine under this Agreement are reserved by Pulmokine and may be used or otherwise exploited by
Pulmokine for any purpose. [***]. In the event of an assignment of this Agreement by Pulmokine in accordance with Section 16.1, no rights or licenses to the intellectual property rights Controlled by Pulmokine’s successor shall be granted
to Licensee by virtue of such an assignment, beyond the rights and licenses that are expressly granted to Licensee by Pulmokine herein. 

2.6. Exclusivity. 
 After
the Effective Date and during the Term, neither Pulmokine nor any of its Affiliates shall research, develop or commercialize, directly or indirectly, or grant any Third Party any rights to any molecule that is an inhibitor of PDGFR kinase, including
the Compound, Backup Compound, Asthma Compounds and Licensed Product; provided, however, that the foregoing shall in no way preclude or otherwise limit Pulmokine’s performance and completion of the ongoing Phase 1A clinical trial, as described
in Pulmokine’s IND 122593 until such time as IND 122593 has been transferred to Licensee or its designee, and Pulmokine’s NIH SBIR Grants (R44HL102946 for PK10571 and 1R43HL132709-01 for asthma) have
been transferred to Licensee or its designee. 
 2.7. Field Expansion Option. 

(a) If Licensee, its Affiliates or Sublicensees identifies a potential application of a Background Product (as defined in the Gilead License)
outside of the Background Patent Field (as defined in the Gilead License), then Licensee may provide Pulmokine notice of such application and request that Pulmokine engage Gilead to request that the field of use be expanded to include the potential
application. Upon receipt of such notice Pulmokine shall engage Gilead to request an amendment to the Gilead License to expand the Background Patent Field (as defined in the Gilead License) up to and including the Broad Field (as defined in the
Gilead License) for the Background Product(s) and, following completion of the same, if successful, Pulmokine shall provide Licensee with written notice thereof accompanied by a copy of such Gilead License amendment (the “Field
Expansion”). Representatives of Licensee may elect to participate with Pulmokine, and Pulmokine shall use good faith efforts to facilitate Licensee’s participation, in any discussions or negotiations with Gilead concerning such
proposed field of use expansion, [***]. To the extent that any additional amounts are required to be paid to Gilead as consideration for the expansion of the field of use, then, prior to amending the Gilead License to expand such field of use,
Pulmokine and Licensee shall discuss in good faith the commercial reasonableness of the consideration required by Gilead for the proposed expansion of the field of use. If such consideration is commercially reasonable Pulmokine shall execute the
amendment and [***]. Licensee shall be permitted to [***] in connection with such 
  

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  
 12 

 
expansion of the field of use [***] that are covered by the Field Expansion but would not have been covered by the Field (as defined in the Gilead License). 

(b) In the event that the Field Expansion includes at least all indication(s) related to [***] and all Future New Inventions (as defined in the
Gilead License) (the [***]), then Licensee [***]. 
 (c) Licensee hereby acknowledges and agrees that Pulmokine’s ability to
successfully amend the Gilead License, as contemplated by this Section 2.7, remains subject to certain factors that are outside of Pulmokine’s reasonable control, [***] the Licensee’s requested amendment(s) of such Gilead License to
expand the field. 
 3. CONSIDERATION 

In consideration of the Licenses and other rights granted to Licensee under this Agreement, Licensee shall pay to Pulmokine the payments as
described in this Article 3. 
 3.1. Up-front Closing and Field Expansion Payment. 

(a) Upon execution of this Agreement, Licensee shall pay to Pulmokine an initial one-time, non-refundable payment (the “Up-front Closing Payment”) equal to five million, and five hundred thousand USD ($5,500,000). 

(b) Licensee shall pay Pulmokine an additional one-time,
non-refundable milestone payment of [***] dollars ($[***]) within [***]. 
 3.2. Development
Milestones. 
 Within [***] of Licensee or its Affiliates or Sublicensees first achieving the following development-related milestone
events with respect to first Licensed Product to achieve such milestone (each, a “Development Milestone”), Licensee will notify Pulmokine in writing thereof and, upon receipt of an invoice from Pulmokine, will pay the
below-specified non-refundable amounts to Pulmokine: 
  

					
	Development Milestone	  	Milestone
Payment (USD)	 
	 [***]
	  	$	[	***] 
	 [***]
	  	$	[	***] 
	 [***]
	  	$	[	***] 
	 [***]
	  	$	[	***] 
	 [***]
	  	$	[	***] 

 For the purposes of this Section 3.2, the term “Licensed Product” shall expressly exclude any
process or tangible material, which, in the course of being practiced, manufactured, used, sold or 
  

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  
 13 

 
imported, would contain or otherwise incorporate one or more of the Biomarkers or other similar subject matter that is the subject of the Biomarker Patents. For clarity, Licensee shall be
required to pay any Development Milestone payment if a subsequent Development Milestone is achieved before a preceding Development Milestone. [***]. 

For clarity, each Development Milestone payment is due only once regardless of the number of Licensed Products developed by Licensee. 

3.3. Regulatory Milestones. 

Within [***] of Licensee or its Affiliates or Sublicensees first achieving the following
regulatory milestone events with respect to the First and Second Licensed Products (each, a “Regulatory Milestone”), Licensee will notify Pulmokine in writing thereof and, upon receipt of an invoice from Pulmokine, will pay the
below-specified non-refundable amounts to Pulmokine: 
  

									
	 Regulatory Milestone
	  	Milestone
Payment For First
Licensed Product (USD)	 	 	Milestone
Payment For
Second Licensed
Product (USD)	 
	 [***]:
	  				 			
	 1. [***]
	  	$	[	***] 	 	 	N/A	 
	 2. [***]
	  	$	[	***] 	 			
	 3. [***]
	  	$	[	***] 	 	$	[	***] 
	 4. [***]
	  	$	[	***] 	 	$	[	***] 
	 5. [***]
	  	$	[	***] 	 	 	[	***] 
	 6. [***]
	  	$	[	***] 	 			
	 7. [***]
	  	$	[	***] 	 	$	[	***] 
	 8. [***]
	  	$	[	***] 	 	$	[	***] 

 For clarity, the milestone payments under this Section 3.3 shall not [***] for the first Licensed
Product, $[***] for the second Licensed Product, or a total of $[***] for all Licensed Products. 
  

 

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  
 14 

 For the purposes of this Section 3.3, the term “First Licensed
Product” shall mean a Licensed Product [***] and the term “Second Licensed Product” shall mean a Licensed Product [***], provided that, for clarity, each of the First Licensed Product and Second Licensed Product shall
[***]. 
 3.4. Sales Milestones. 

Within [***] of Licensee or its Affiliates or Sublicensees first achieving the following sales-related milestone events during the Royalty
Term with respect to aggregate annual Net Sales of the Licensed Products (each, a “Sales Milestone”), Licensee will notify Pulmokine in writing thereof and, upon receipt of an invoice from Pulmokine, pay the below-specified amounts
to Pulmokine: 
  

					
	 Sales Milestone
	  	Milestone
Payment (USD)	 
	 [***]
	  	$	[	***] 
	 [***]
	  	$	[	***] 
	 [***]
	  	$	[	***] 
	 [***]
	  	$	[	***] 

 For clarity, each Sales Milestone payment is due only once regardless of the number of Licensed Products commercialized by
Licensee or the number of times the Sales Milestone is met. 
 3.5. Royalty. 

During the Royalty Term, on a License Product-by-Licensed
Product basis, Licensee shall pay to Pulmokine royalty payments at the following royalty rates on the applicable portion of the cumulative Territory-wide Calendar Year Net Sales of all Licensed Products: 

 

			
	 Cumulative Calendar Year Net Sales of the Licensed Products
	  	Royalty Rate
		
	 Portion of cumulative Calendar Year Net Sales of Licensed Products in the Territory up to and including
USD $[***]
	  	[***]%
	 Portion of cumulative Calendar Year Net Sales of Licensed Products in the Territory between USD $[***]and
USD $[***]
	  	[***]%
	 Portion of cumulative Calendar Year Net Sales of Licensed Products in the Territory exceeding
USD $[***]
	  	[***]%

  
  

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  
 15 

 3.6. Sublicensing Income and Purchaser Income. 

(a) Licensee shall pay to Pulmokine a percentage of all Sublicense Income and Purchaser Income received by Licensee or its Affiliates at the
following rates: 
 (i) [***] percent ([***]%) [***] Sublicensee or a Third Party purchaser (“Purchaser”) pursuant to a
sublicense or purchase agreement entered into with such a Sublicensee or Purchaser prior to [***]; 
 (ii) [***] percent ([***]%) of
Sublicense Income or Purchaser Income paid to, or earned or accrued by, Licensee or its Affiliates from a Sublicensee or Purchaser pursuant to a sublicense or purchase agreement entered into with such a Sublicensee or Purchaser after the milestone
in subparagraph (a) and [***]; and 
 (iii) [***] percent ([***]%) of Sublicense Income or Purchaser Income paid to, or earned or
accrued by, Licensee or its Affiliates from a Sublicensee or Purchaser pursuant to a sublicense or purchase agreement entered into with such a Sublicensee or Purchaser [***]. 

(b) For any Purchaser Income due to Pulmokine pursuant to Section 3.6(a) [***]. 

(c) For payments for Sublicense Income that is earned or accrued in the relevant time period under this Section 3.6, such payments shall
be due Pulmokine on Licensee’s or its Affiliates’ actual receipt of such Sublicense Income [***]. For clarity, no payments for Sublicensing Income or Purchaser Income shall be due to Pulmokine unless actually received by Licensee or its
Affiliates. 
 (d) For purposes of this Section 3.6, “Sublicense Income” means [***], received by Licensee or its
Affiliates from a Sublicensee pursuant to a sublicense of one or more of the Licensed Patents granted pursuant to this Agreement; and “Purchaser Income” means any payment received by Licensee or its Affiliates from a Third Party
[***], or a Change of Control of Licensee. Not included in Sublicensing Income or Purchaser Income is any other consideration received by Licensee or its Affiliates from a Sublicensee or Purchaser, including income received by Licensee (i) [***];
(ii) [***]; (iii) [***]; (iv) [***]; (v) [***], (vi) [***], and/or (vii) [***]. 
 3.7. Royalty Payment Timing; Reports of Net Sales.

 Within forty five (45) days following the end of each Calendar Quarter during which royalties accrue, Licensee shall provide to
Pulmokine a quarterly report on Net Sales of Licensed Products during such Calendar Quarter. Such report shall include a written report in reasonable detail of: (a) the Net Sales of Licensed Products for the previous Calendar Quarter, broken
down by country and product, (b) the royalty payment that is due and payable, and (c) the basis for calculating such royalty payment including the gross sales of Licensed Products by country and product, the rate of currency conversion and
date such conversion was calculated. [***]. 
  
  

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  
 16 

 3.8. Audits. 

During the Royalty Term, Licensee shall keep records pertaining to the sale or other disposition of Licensed Products by Licensee, its
Affiliates and Sublicensees in sufficient detail to permit Pulmokine to confirm the accuracy of the royalties and Sales Milestone payments due hereunder. All such records shall be kept at Licensee’s principal place of business for a period of
not less than [***] following the end of the Calendar Year to which they pertain. Pulmokine shall have the right to cause an independent accounting firm reasonably acceptable to Licensee to audit
such records for the purpose of confirming Net Sales and royalties. Such audits may be exercised during normal business hours upon reasonable prior written notice (not to be less than thirty (30) days) to Licensee. Upon request, such accounting
firm shall execute a confidentiality agreement with Licensee prior to commencing the audit. Adjustments (including remittances of underpayments or overpayments disclosed by such audit) shall be made by the Parties to reflect the results of such
audit, which adjustments shall be paid promptly following receipt of an invoice therefor. Pulmokine shall bear the full cost and expense of such audit unless such audit discloses an underpayment by Licensee of [***] percent ([***]%) or more of the
amount of royalties due under this Agreement for the audited period, in which case Licensee shall bear the cost and expense of such audit. 

If Licensee in good faith disputes the conclusion of the accounting firm under the first paragraph of this Section 3.8 that Licensee owes
additional royalties or other payments, or any specific aspect of the conclusion, then Licensee will inform Pulmokine by written notice within sixty (60) days of receiving a copy of the audit containing such conclusion, specifying in detail the
reasons for Licensee’s disputing such conclusion. The Parties will promptly thereafter meet and negotiate in good faith a resolution to such dispute. 

3.9. Currency. 
 All
payments under this Article 3 will be made in USD. With respect to sales of Licensed Products invoiced in a currency other than USD, all amounts reported and payable under this Agreement shall be calculated based on the domestic currency where such
sale is made and converted (as applicable) into the USD equivalent. The USD equivalent shall be calculated in accordance with U.S. GAAP. 

3.10. Account. 
 All
payments to be made to Pulmokine under this Agreement will be made by wire transfer to the following account: 
 [***] 

or such other account as may be specified by Pulmokine in writing to Licensee. 

 
  

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  
 17 

 3.11. Taxes. 

Each Party shall be responsible for any and all taxes required by Law that are levied on the payments it receives under this Agreement. If
applicable Law requires that taxes be withheld from a payment made by FSG to Pulmokine under this Agreement, FSG shall (a) deduct those taxes from the remittable payment, (b) pay the taxes to the proper taxing authority, and (c) send
evidence of the obligation together with proof of payment to Pulmokine within thirty (30) days following that payment. Each Party agrees to cooperate with the other Party in claiming exemption from such deductions or withholdings under any
relevant agreement or treaty which is in effect and, to the extent permitted by applicable Law, minimizing the amount of tax payable with respect to payments made and received under this Agreement. In addition, the Parties shall cooperate in
accordance with applicable Law to minimize indirect taxes (such as value added tax, sales tax, consumption tax and other similar taxes) in connection with this Agreement. 

3.12. Interest on Late Payments. 

Interest shall be payable on any payments that are not paid on or before the date [***]
after the date such payments are due under this Agreement at the per-annum rate of prime (as reported in The Wall Street Journal (U.S., Eastern Edition)) plus [***] percentage points or the maximum rate
allowable by Law, whichever is less. 
 3.13. Permitted Reductions. 

Notwithstanding the provisions of Section 3.5, 

(a) in the event that Licensee reasonably determines that it is necessary for Licensee to obtain a license from a Third Party to research,
develop, make, have made, use, offer to sell, sell, have sold or import any Licensed Product (“Additional Third Party Licenses”) and Licensee obtains such an Additional Third Party License, then Licensee may deduct from the royalty
payment that would otherwise have been due to Pulmokine, an amount equal to [***] percent ([***]%) of the royalties actually paid to such Third Party under such Additional Third Party Licenses by Licensee to research, develop, make, have made, use,
offer to sell, sell, have sold or import, as applicable, such Licensed Product; provided, that in the case of [***], this Section 3.13(a) applies [***] provided, further, that in no event shall the royalties owed by Licensee to Pulmokine be
reduced by more than [***] percent ([***]%) pursuant to this paragraph 3.13(a); 
 (b) in the event that, on a Licensed Product-by-Licensed Product and country-by-country basis, Generic Product Competition is
present with respect to such Licensed Product in such country, then [***] Net Sales of such Licensed Products in such countries, and for purposes of this paragraph, “Generic Product Competition” shall mean with respect to a Licensed
Product on a country-by-country basis, [***]; 
 (c) in
countries in the Territory where a Licensed Product is not Covered by a Valid Claim of a Licensed Patent in the country of sale and there is no Marketing Exclusivity in such countries for the Licensed Product, [***] in such countries with respect to
the Royalty Term [***]; and 
 (d) Except as otherwise set forth in Section 3.13(b), in no event shall the royalties owed by Licensee to
Pulmokine for a particular Licensed Product be reduced to less than the amount owed by Pulmokine under the Gilead License and the RCTR License for such Licensed Product. 
  

 

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  
 18 

 3.14. FSG Guaranty. 

FSG irrevocably and unconditionally guarantees the payment of each and every payment obligation of Licensee to Pulmokine under this Article 3,
whether now existing or hereafter arising. FSG shall promptly pay to Pulmokine any amount properly due to Pulmokine upon demand following any failure on the part of Licensee to cure a payment default in accordance with Section 15.3, provided
that Pulmokine is not then in breach of this Agreement, Pulmokine waives the Licensee’s corresponding payment default (subject to FSG’s cure thereof), and any and all then exiting breaches (or alleged breaches) of the Agreement by Licensee
that are known to Pulmokine shall be made known to Licensee and FSG at the time of Pulmokine’s demand following such a failure on the part of Licensee. Notwithstanding anything to the contrary herein, FSG’s obligations under this
Section 3.14 shall exists only as long as Licensee is an Affiliate of FSG and Licensee has not assigned this Agreement to a third party. 
 4.
DEVELOPMENT AND COMMERCIALIZATION OF LICENSED PRODUCTS 
 4.1. Know-How and Regulatory
Filings. 
 Pulmokine shall disclose to Licensee, at Pulmokine’s cost and expense, the Licensed
Know-How as Controlled by Pulmokine as of the Effective Date, including all Scientific Information, Data and other Information related to the Compound, the Backup Compound, the Asthma Compounds, Biomarkers and
Licensed Products. Subject at all times to Section 15.7, Pulmokine shall transfer all Regulatory Filings existing as of the Effective Date for the Compound, Backup Compound, Asthma Compounds, Biomarkers and Licensed Products in the Licensed
Product Field in the Territory to Licensee. All Licensed Know-How required to be disclosed and all Regulatory Filings required to be transferred under this Section 4.1 shall be the Confidential
Information of Licensee. 
 4.2. General. 

Except as expressly set forth herein, Licensee (either by itself or through its Affiliates or Sublicensees) shall be solely responsible for and
shall use Commercially Reasonable Efforts to develop and commercialize at least one (1) Licensed Product that contains or otherwise incorporates one or more of the [***] in the Licensed Product Field in the United States and at least two
(2) countries in the European Union, at its own cost and expense. 
 The Licensee shall report to Pulmokine the dates of the First
Commercial Sale of each Licensed Product in each country in the Territory within fourteen (14) days of such occurrences. Additionally, with respect to any Licensed Product that contains or otherwise incorporates [***], Licensee agrees to:
(a) use its Commercially Reasonable Efforts to [***]; (b) upon the First Commercial Sale thereof and continuing until the expiration or termination of this Agreement, [***]; (c) after the First Commercial Sale thereof, to [***]; (d) after the
First Commercial Sale and as part of its [***]; and (e) to [***]. For the purposes of this Section 4.2, the term “Practical Application” means to manufacture in the case of a composition or product, to practice in
the case of a process or method, or to operate in the case of a machine or system; and in each case, under these conditions as to establish that the invention that is the subject of [***] and that its benefits are to the extent permitted by law or
regulations of the United States Government available to the public on reasonable terms. 
  

 

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  
 19 

 4.3. Regulatory. 

Except as expressly set forth herein, Licensee shall have the sole right to apply for and maintain, at Licensee’s cost and expense, all
Regulatory Approvals of Licensed Products in the Licensed Product Field in the Territory. [***]. Licensee shall have the sole right to prepare, file and otherwise handle all regulatory materials and all communications and interactions with
Regulatory Authorities with respect to Licensed Products in the Licensed Product Field in the Territory, both prior to and subsequent to Regulatory Approval. Unless otherwise prohibited by Applicable Law, [***] concerning a Licensed Product.
Licensee shall have the sole right to file and maintain all required regulatory dossiers to obtain (and maintain) Regulatory Approvals of Licensed Products in the Licensed Product Field in the Territory and shall be the holder of any such Regulatory
Approvals. Pulmokine shall reasonably cooperate with Licensee in obtaining Regulatory Approvals of Licensed Products. Licensee shall have sole responsibility and control with respect to all safety and pharmacovigilance activities with respect to the
Licensed Products under Law, and Pulmokine agrees to provide Licensee with any safety or pharmacovigilance-related Information in Pulmokine’s possession, as Licensee may reasonably request from time to time. 

4.4. Reporting. 
 Licensee
shall keep Pulmokine reasonably informed on the development and commercialization of the Licensed Products, including with respect to receipt of any Regulatory Approvals. During the period beginning with the commencement of the Phase 2 Clinical
Trial for the initial Licensed Product, and ending on the date of receipt of Regulatory Approval for such Licensed Product, Licensee shall provide Pulmokine with reasonably detailed written reports [***] summarizing Licensee’s activities with
respect to the development of the Licensed Product since the last such report. In addition, Licensee shall provide Pulmokine with reports under Section 3.7. 

4.5. Supply of Licensed Product. 

Except as otherwise agreed upon by the Parties, Licensee shall be solely responsible for manufacturing or having manufactured, at its cost and
expense and in accordance with applicable Law, sufficient clinical and commercial quantities of the Licensed Product to fulfill Licensee’s development and commercial obligations hereunder. Notwithstanding the foregoing, upon request by
Licensee, Pulmokine shall sell to Licensee at Pulmokine’s cost of goods plus delivery costs some or all quantities of the Backup Compound or Asthma Compounds active pharmaceutical ingredient (API) and/or Licensed Product containing same and/or
Biomarkers in Pulmokine’s possession and some or all quantities of the Compound active pharmaceutical ingredient (API) and/or Licensed Product containing same in Pulmokine’s possession following its completion of the Phase 1A clinical
trial. 
 4.6. Technology Transfer. 

As soon as reasonably practicable after the Effective Date, Pulmokine shall disclose and deliver to Licensee (or its designee) all tangible
embodiments of all Licensed Know-How in its possession and Control that is useful or necessary to research, develop, make ,use, sell, offer for sale or import the Licensed Products. Pulmokine shall make such
Licensed Know-How available in a mutually agreed upon format and where feasible in electronic form. Without limiting the foregoing, Pulmokine will provide reasonable assistance to Licensee or its designee in
connection with understanding and using the Licensed Know-How related to the Licensed Products, including assistance from its professional staff for meetings, telephone calls, and other reasonable assistance
as requested by Licensee to enable it to understand and use such Licensed Know-How. In addition, upon the reasonable request of Licensee, Pulmokine shall reasonably cooperate with Licensee to transition the
manufacture of the applicable Licensed Products to a contract 
  

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  
 20 

 
manufacturing organization designated by Licensee. Licensee agrees to reimburse Pulmokine for its reasonable costs and expenses incurred in connection with Pulmokine’s delivery of the
Licensed Know-How and the provision of related support under this Section 4.6, provided that Pulmokine provides documentation of such costs and expenses reasonably acceptable to Licensee. All information
and material required to be disclosed and delivered under this Section 4.6 shall be the Confidential Information of Licensee. 
 5. JOINT
DEVELOPMENT COMMITTEE 
 5.1. Formation; Composition. 

Within thirty (30) days after the Effective Date, the Parties shall establish a Joint Development Committee composed of no more than three
(3) representatives of each Party. Each Party may change its representatives to the JDC from time to time in its sole discretion, effective upon notice to the other Party of such change. These representatives shall have appropriate technical
credentials, experience and knowledge. A reasonable number of additional representatives of a Party may attend meetings of the JDC in a non-voting capacity. After its establishment, the JDC shall remain in
place until the initial Regulatory Approval of the initial Licensed Product, unless otherwise agreed by the Parties in writing. A JDC member appointed by Licensee shall serve as chairperson of the JDC. 

5.2. Responsibilities. 

The JDC’s overall responsibility shall be to encourage and facilitate ongoing cooperation between the Parties with respect to the
development activities contemplated by this Agreement and to perform the other obligations specifically delegated to it by this Agreement, subject to the limitations set forth in this Article 5. The JDC shall also serve as the principal means by
which Licensee keeps Pulmokine informed regarding Licensee’s development plans, efforts and results with respect to Licensed Products in the Licensed Product Field in the Territory, including without limitation: (a) providing a forum for
the Parties to discuss regulatory, scientific and/or clinical matters and objectives relating to the development of such Licensed Products; (b) discussing and reviewing the progress and Data relating to the development of such Licensed Products
and the Parties’ performance relative to any established objectives; and (c) performing such other functions as appropriate to further the purposes of this Agreement, as mutually agreed upon by the Parties in writing. 

5.3. Decision-Making. 

The JDC shall operate by unanimous consent of its members. In the event of an unresolved dispute regarding any development activities related
to the Licensed Product in the Licensed Product Field in the Territory, the position of the members of the JDC appointed by Licensee shall control; [***]. The JDC shall not have the power to amend or waive compliance with this Agreement, or to
resolve any disputes relating to intellectual property rights, including disputes relating to the inventorship, enforceability, validity or scope of patent or other intellectual property rights. 

5.4. Meetings. 
 Unless
otherwise agreed upon by the Parties the JDC shall meet at least once [***] every Calendar Quarter, in each case at times mutually agreed upon by the Parties. At least one (1) of such 

 
  

 

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  
 21 

 
meetings per Calendar Year shall be held in person, and all other such meetings may be held by teleconference or videoconference. The location of the meetings of the JDC to be held in person
shall be agreed upon by the Parties. Each Party shall bear all expenses of its representatives on the JDC. 
 5.5. Meeting Agenda;
Minutes. 
 The JDC chairperson shall be responsible for preparing and circulating an agenda in advance of each meeting of the JDC and
for preparing and issuing minutes of each meeting within thirty (30) days thereafter. Such minutes will not be finalized until both Parties’ representatives on the JDC review and confirm the accuracy of such minutes in writing. Each Party
will disclose to the other Party any other proposed agenda items along with appropriate information at [***] Business Days in advance of each meeting of the JDC; provided that, under exigent circumstances requiring the JDC’s input, a Party may
provide its agenda items to the other Party within a lesser period of time in advance of the meeting so long as such other Party consents to such later addition of such agenda items for such JDC meeting. 

5.6. Dissolution on Change of Control. 

At any time following the completion of the ongoing Phase IA clinical trial, Licensee may, in its sole discretion, dissolve the JDC in the
event of a Change of Control of Pulmokine. 
 6. INTELLECTUAL PROPERTY 

6.1. Patent Prosecution and Maintenance. 

As between the Parties, Licensed Patents shall be diligently prepared, filed, prosecuted and maintained by Pulmokine and in accordance with
this Section 6.1. [***], and Licensee shall reimburse Pulmokine for [***] of receipt of invoice therefor. [***] Pulmokine shall: (a) keep Licensee reasonably informed of the preparation, filing, prosecution and maintenance of Licensed
Patents, (b) provide Licensee with the opportunity to review and comment on any and all such prosecution efforts, and in no event less than thirty (30) days prior to any filing deadlines, provide Licensee copies of all documents relevant
to any such prosecution efforts, including any drafts of any material filings or responses to communications with Regulatory Authorities, (c) take into consideration in good faith any comments from Licensee on such prosecution efforts, and
(d) provide Licensee with a copy of all material communications from Regulatory Authorities in the Territory regarding the Licensed Patents. If Pulmokine desires to [***] allow any Licensed Patents to lapse or to abandon any Licensed Patents,
Pulmokine shall notify Licensee in writing not less than [***] prior to taking such action [***] and [***] Licensee shall have the right (but not the obligation) to assume the responsibility for and control of the prosecution and maintenance of such
Licensed Patents, as applicable, [***]. 
 6.2. Enforcement of Intellectual Property Rights. 

(a) General. Each Party will promptly notify the other Party of any infringement or misappropriation or suspected infringement or
misappropriation that may come to its attention relating to the Licensed Technology and will provide the other Party with reasonable information with respect thereto. 

(b) Licensee First Right in the Territory. If a Third Party infringes or misappropriates any Licensed Patents or Licensed Know-How and such infringement or misappropriation relates to Licensed Products in the Licensed Product Field in the Territory, then, [***], as applicable, [***] will have the first 

 
  

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  
 22 

 
right (but not the obligation), at its own expense, to pursue any and all remedies against such Third Party, and [***] will have the right to participate in such action at its own expense. [***],
as applicable, should [***] determine not to pursue remedies with respect to any such infringement or misappropriation of Licensed Patents or Licensed Know-How within (a) [***] following the notice of
alleged infringement or (b) [***] before the time limit, if any, set forth in the applicable Laws for the filing of such actions, whichever comes first, then [***] will have the right (but not the obligation), at its own expense, to pursue
remedies against such Third Party with respect to the Licensed Patents and Licensed Know-How, and [***] shall have the right to participate in such action at its own expense. 

(c) Assistance and Cooperation; Recoveries. If a Party pursues remedies hereunder with respect to infringement or misappropriation of
Licensed Patents or Licensed Know-How, the other Party shall assist and cooperate fully with the Party pursuing such remedies, including, if required to bring such action, joining in any action as set forth in
this Section 6.2 or providing a power of attorney. [***], as applicable, [***], any damages or other amounts collected will be distributed, first, to the Party that pursued remedies to cover its costs and expenses and, second, to the other
Party to cover its costs and expenses, if any, relating to the pursuit of such remedies; and any remaining amount will be distributed to the Parties in equal amounts; [***]. 

(d) Settlement of Litigation. No settlement, consent judgment or other final disposition of an action for infringement or validity or
misappropriation may be entered into as to any Licensed Patents or Licensed Know-How in the Licensed Product Field without the prior written consent of Licensee, which consent shall not be unreasonably
withheld. 
 6.3. Third Party Actions. 

If a Third Party institutes (a) a patent, trade secret or other infringement or misappropriation suit against Licensee during the Term,
alleging that the manufacture, marketing, sale, use, importation, exportation or other exploitation of the Licensed Products infringes or misappropriates one (1) or more patent or other intellectual property rights held by such Third Party or
(b) an opposition, re-examination request, action for declaratory judgment, nullity action, interference, inter partes review, challenge related to a certification filed pursuant to 21 U.S.C. §
355(b)(2)(A) or §355(j)(2)(A)(vii)(IV) or its successor provisions or a similar action under foreign Laws, or other attack upon the validity, title or enforceability of the Licensed Patents, then Licensee will have the sole right (but not the
obligation) to assume direction and control of the defense of such claims. At Licensee’s request, Pulmokine will provide reasonable assistance in connection with the defense of such claims, including, at either Party’s request, the entry
into a “common interest agreement” as may be appropriate. Each Party shall bear its own expenses incurred in connection with the defense of such claims. 

6.4. Ownership of Inventions. 

(a) Inventorship. Inventorship of inventions and discoveries conceived and reduced to practice during the Term shall be
determined in accordance with the rules of inventorship under United States patent laws. Pulmokine shall solely own all patent applications and patents that encompass all such inventions and discoveries that are solely invented by Pulmokine, which,
if necessary or useful to the research, development, manufacture, commercialization, sale, use or other exploitation of the Compound, Backup Compound, Asthma Compounds, Biomarkers or Licensed Products, shall constitute Licensed Patents and be
subject to the terms and conditions of this Agreement. Licensee shall solely own and shall bear all expenses incurred in preparing, filing, prosecuting and maintaining all patent applications and patents that encompass all such inventions and
discoveries that are solely invented by Licensee, its 

  
 23 

 
Affiliates or Sublicensees, and which for the purposes hereof shall include any Improvements made solely by Licensee (the “Licensee Inventions”). 

(b) Joint Inventions. The Parties do not intend to conduct any activities which could result in inventions or discoveries in which one
(1) or more employees, officers, directors, contractors or agents of Licensee, its Affiliates or Sublicensees and one (1) or more employees, officers, directors, contractors or agents of Pulmokine have contributed to the conception of such
invention or discovery, and which for the purposes hereof shall include any Improvements (whether such Improvements were solely or jointly made, developed, conceived or reduced to practice by Pulmokine, but excluding Improvements made solely by
Licensee) (collectively, “Joint Inventions”). In the unlikely event that Joint Inventions are conceived and reduced to practice during the Term, Pulmokine and Licensee shall jointly own all right, title and interest in and to such
Joint Inventions, and Pulmokine’s rights in such Joint Inventions shall be automatically included in the Licensed Technology licensed to Licensee under Section 2.1 without additional consideration, except as provided in Section 6.1.
Each Party will promptly, but in no event later than thirty (30) days from invention, creation or conception, inform the other Party of all Joint Inventions. Information provided with respect to such Joint Inventions will be in reasonable
detail but in no circumstance less than would be sufficient to permit an understanding of the nature of such Joint Inventions by a practitioner reasonably skilled in the relevant technical or scientific area. Notwithstanding anything set forth in
Section 8.1 to the contrary, to the extent that any such Joint Inventions constitute a Future New Invention (as defined in the Gilead License), then Pulmokine shall provide Gilead with notice thereof in accordance with the terms of such Gilead
License 
 (c) Trademarks. In its sole discretion, Licensee will own and shall have sole responsibility and control with respect to
all trademarks related to its commercialization and other exploitation of Licensed Products and with respect to registering, defending and maintaining such trademarks. 

6.5. Patent Cooperation. 

Pulmokine shall make its employees, agents and consultants reasonably available to Licensee (or Licensee’s authorized attorneys, agents or
representatives) at Licensee’s expense, to the extent reasonably necessary to enable Licensee to undertake preparation, filing, prosecution and maintenance of the Licensee Inventions. 

6.6. Orange Book. 
 In the
event that one (1) or more Licensed Patents contains a claim or claims that must be submitted for a Licensed Product covered by such patent pursuant to 21 C.F.R. § 314.53 or its successor and subsequently be listed in the Approved Drug
Products with Therapeutic Equivalence Evaluations published by the FDA Center for Drug Evaluation and Research or any successor publication (the “Orange Book”), Licensee shall promptly confer with Pulmokine regarding the same
and, following which Licensee shall have the right in its sole discretion to file with the FDA the required listing documents and certifications, and Pulmokine will sign any power of attorney, and do such other lawful acts, in each case as are
required by FDA to effect such submission as required under 21 C.F.R. § 314.53(c)(2)(ii) or its successor. 

  
 24 

 6.7. Patent Term Extensions.

Licensee shall have the right to prepare and file, or to cause Pulmokine [***] to prepare and file, a patent term extension or supplementary
protection certificate application with respect to any applicable Licensed Patent upon Regulatory Approval of a Licensed Product (which is Covered by such Licensed Patent), and the Parties will cooperate with each other and use reasonable efforts to
obtain all available extensions and supplementary protection certificates for any such Licensed Patent applicable to such Licensed Product. Each Party shall be permitted to assist and provide comments to the other Party, and to provide the
regulatory timeline, diligence and regulatory period calculations required as part of the application, to complete the application(s) for such extensions or supplementary protection certificates and to assist in any other matters related to
preparation of the application(s) for such extensions or supplementary protection certificates, and each Party will fully cooperate, in preparing and filing such a patent term extension or supplementary protection certificate application with
respect to any such Licensed Patent within the limited time set for filing such application. All term extensions under this Section 6.7 shall be owned by Pulmokine, except to the extent that the applicable Licensed Patent is a Pulmokine-Gilead Joint
Patent, in which event the term extension shall be jointly owned by Pulmokine and Gilead. 
 7. REPRESENTATIONS, WARRANTIES AND COVENANTS 

7.1. No Litigation. 
 Each
Party represents and warrants to the other Party that, to its knowledge as of the Effective Date, there is no litigation, proceeding or investigation pending or threatened against or involving such Party in any court or before any agency or
regulatory body which could adversely affect such Party’s ability or right to carry out the transactions contemplated by this Agreement. 

7.2. No Debarment. 

Neither Party, nor any of such Party’s employees, independent contractors, consultants, agents or officers: (a) has ever been
debarred or is subject to debarment or, to such Party’s knowledge, convicted of a crime for which a Person could be debarred before a Regulatory Authority under applicable Laws, or (b) to such Party’s knowledge, has ever been under
indictment for a crime for which a Person could be debarred under such Laws. 
 7.3. Corporate Existence. 

As of the Effective Date, each Party represents and warrants to the other Party that it is a company duly organized, validly existing and in
good standing under the Laws of the jurisdiction in which it is formed. 
 7.4. Authority to Execute and Perform. 

As of the Effective Date, each Party represents, warrants and covenants to the other that it: 

(a) has the power and authority and the legal right to enter into this Agreement and to perform its obligations hereunder; 

(b) has taken all necessary company action on its part required to authorize the execution and delivery of this Agreement; 

 
  

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  
 25 

 (c) has duly executed and delivered this Agreement, which constitutes a legal, valid and
binding obligation of it and which is enforceable against it in accordance with this Agreement’s terms; and 
 (d) shall perform its
obligations hereunder in compliance with applicable Laws. 
 7.5. Non-Contravention. 

As of the Effective Date, Pulmokine represents and warrants to Licensee that the execution, delivery and performance of this Agreement by it,
and the transactions contemplated hereby, do not and will not: 
 (a) conflict with or result in a breach of any provision of the corporate
charter, certificate of incorporation, by-laws or organizational documents of Pulmokine or any of its Affiliates; 

(b) conflict with, result in a breach or default or give rise to any right of termination, cancellation, modification or acceleration under any
contract, agreement or instrument related to the Licensed Patents, Licensed Know-How or Licensed Products to which Pulmokine or any of its Affiliates is a party (including the Gilead License and the RCTR
License) or to which Pulmokine or any of its Affiliates may be subject although not a party; 
 (c) violate any applicable Laws; or 

(d) result in the imposition of any lien or encumbrance upon any Licensed Patent, Licensed Know-How or
Licensed Product. 
 7.6. Additional Pulmokine Representations, Warranties and Covenants. 

Pulmokine represents, warrants and covenants to Licensee that: 

(a) Pulmokine is the sole and exclusive owner of the entire right, title and interest in and to the Pulmokine-Controlled Patents on Exhibit
E and the Asthma Patent on Exhibit G free and clear of all liens and other encumbrances, security interests, options and licenses; 

(b) Pulmokine is the joint owner (together with Gilead) of a joint and undivided right, title and interest in and to the Pulmokine-Gilead Joint
Patents on Exhibit F free and clear of all liens and other encumbrances, security interests, options and licenses and is the exclusive licensee in the Licensed Product Field of all of Gilead’s joint and undivided right, title and
interest in and to such Pulmokine-Gilead Joint Patents, and holds such license free and clear of all liens and other encumbrances, security interests, options and licenses; 

(c) Pulmokine is the exclusive licensee in the Licensed Product Field of the Gilead Background Patents on Exhibit C, the exclusive
licensee of the Biomarker Patents on Exhibit H, and holds each license for such patent rights free and clear of all liens and other encumbrances, security interests, options and licenses; 

(d) [***] the Licensed Patents set forth on Exhibit G, Exhibit H, Exhibit C, Exhibit E, and Exhibit F
constitute all the patents and patent applications owned or Controlled by Pulmokine that Cover the Biomarkers, Compound, the Backup Compound and the Asthma Compounds; 

 

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  
 26 

 (e) Pulmokine has the right to grant the licenses and rights in the Licensed Patents it
purports to grant to Licensee hereunder; 
 (f) During the Term, Pulmokine shall maintain the Gilead License and the RCTR License in good
standing and shall not take any action, or omit to take any action (including making necessary payments), which would result in a breach or early termination of the Gilead License, the RCTR License or any rights thereunder. Pulmokine covenants that
it shall not amend, modify or supplement the terms of, or waive any rights under, the Gilead License or RCTR License that would adversely impact Licensee’s rights hereunder without the prior written consent of Licensee, such consent not to be
unreasonably withheld, delayed or conditioned. Pulmokine shall promptly notify Licensee upon receipt by Pulmokine of any notice from Gilead or RCTR of any actual or alleged breach under the Gilead License or RCTR License, as applicable, and
Pulmokine shall promptly cure any such breach within the allotted cure period and if it is unwilling or unable to do so, Pulmokine shall timely notify Licensee and Licensee shall have the right to cure such breach on Pulmokine’s behalf; 

(g) There are no adverse actions, suits or claims pending or, [***], threatened against Pulmokine in any court or by or before any governmental
entity with respect to the Compound, the Backup Compound, Biomarkers or Asthma Compounds or the Licensed Technology and, to the actual knowledge of Pulmokine, with the exception of certain of the Gilead Background Patents, there are no Third Party
patents that would reasonably be expected to give rise to such actions, suits or claims. No Third Party has challenged the ownership, scope, duration, validity, enforceability, priority or right to use the Licensed Technology; 

(h) Pulmokine has not initiated or been involved in any proceedings or claims in which it alleges that any Third Party is or was infringing or
misappropriating the Licensed Technology, nor have any proceedings been threatened by Pulmokine, nor to the knowledge of Pulmokine is there any basis for any such proceeding; and 

(i) With the exception of certain of the Gilead Background Patents, [***] and notwithstanding 35 U.S.C. § 271(e) or any comparable Laws,
the research, development, manufacture, use or sale of the Compound, the Backup Compound, the Asthma Compounds or the Biomarkers does not infringe or misappropriate any patent rights, know-how rights, or other
intellectual property rights of any Third Party. 
 7.7. No Implied Warranties. 

Except as expressly set forth in this Agreement, Pulmokine makes no other representation or warranty, express or implied, with respect to the
subject matter hereof or the transactions contemplated hereby. 
 8. CONFIDENTIALITY OBLIGATIONS OF PULMOKINE 

8.1. Confidentiality Obligations. 

Subject to Article 10, during the Term and for a period of (x) seven (7) years thereafter with respect to
non-disclosure obligations and (y) three (3) years thereafter with respect to non-use obligations, Pulmokine: 

(a) shall hold in strict confidence any and all information disclosed to it or its Affiliates by or on behalf of Licensee or its Affiliates or
Sublicensees, whether pursuant to this Agreement or the Confidentiality Agreement, all Licensed Know-How required to be disclosed and all Regulatory Filings required to be transferred under Section 4.1,
and all information and material required to be disclosed and 

  
 27 

 
delivered under Section 4.6 (collectively “Licensee Confidential Information”) and, subject to Section 15.7(a), shall not use, nor disclose or supply to any Third
Party, nor permit any Third Party to have access to Licensee Confidential Information, without first obtaining the written consent of Licensee, except in connection with the performance of its obligations and exercise of its rights under this
Agreement; 
 (b) shall take all reasonable precautions necessary or prudent to prevent material in its possession or control that contains
or refers to Licensee Confidential Information from being destroyed or lost, or discovered, received, used, intercepted or copied by any Third Party; and 

(c) may disclose Licensee Confidential Information only to its employees, consultants, independent contractors, agents, Affiliates and actual
or potential acquirers, in each case solely to the extent reasonably necessary for the purposes of, and for those matters undertaken pursuant to, the performance of Pulmokine’s obligations and exercise of Pulmokine’s rights under this
Agreement; provided, in each case, that such employees, consultants, independent contractors, agents, Affiliates and actual or potential sources of funding and/or acquirers are bound by terms and conditions of confidentiality of a scope no less
protective than the terms and conditions that bind Pulmokine hereunder. 
 For the avoidance of doubt, it is understood that Pulmokine shall
be liable for any breach of the confidentiality obligation under this Section 8.1 by any person or corporation to whom Licensee Confidential Information is disclosed by Pulmokine. 

8.2. Exceptions. 

Pulmokine’s obligations of confidentiality and non-use under Section 8.1 shall not apply to,
and Pulmokine shall have no further obligations with respect to, any of the Licensee Confidential Information, to the extent Pulmokine can establish by competent proof that such Licensee Confidential Information: 

(a) is or becomes part of the public domain without breach by Pulmokine of this Agreement; 

(b) was in Pulmokine’s possession before disclosure by Licensee and was not acquired directly or indirectly from Licensee, as documented
by Pulmokine’s written records; 
 (c) is obtained from a Third Party with no obligation of confidentiality to Licensee, who has a right
to disclose it to Pulmokine; 
 (d) is developed independently by Pulmokine without use of or reference to the Licensee Confidential
Information, as evidenced by Pulmokine’s written records; or 
 (e) is required to be revealed in response to a court decision or
administrative order, or to comply with applicable Laws or applicable rules of any Regulatory Authority; provided that, in each such case, Pulmokine shall inform Licensee immediately by written notice and cooperate with Licensee using Commercially
Reasonable Efforts either to enable Licensee to seek protective measures for such Licensee Confidential Information, or to seek confidential treatment of such Licensee Confidential Information, and in such case Pulmokine shall disclose only such
portion of the Licensee Confidential Information which is so required to be disclosed. 
 Any combination of features or disclosures shall
not be deemed to fall within the foregoing exclusions merely because individual features are published or available to the general public or in the rightful possession of Pulmokine unless the combination itself and principle of operation are
published or available to the general public or in the right possession of Pulmokine. 

  
 28 

 9. CONFIDENTIALITY OBLIGATIONS OF LICENSEE 

9.1. Confidentiality Obligations. 

Subject to Article 10, during the Term and for a period of seven (7) years thereafter, Licensee: 

(a) shall hold in strict confidence any and all information disclosed to it or its Affiliates by or on behalf of Pulmokine or its Affiliates or
licensors, whether pursuant to this Agreement or the Confidentiality Agreement (collectively “Pulmokine Confidential Information”) and shall not use, nor disclose or supply to any Third Party, nor permit any Third Party to
have access to Pulmokine Confidential Information, without first obtaining the written consent of Pulmokine, except in connection with the performance of its obligations and exercise of its rights under this Agreement; 

(b) shall take all reasonable precautions necessary or prudent to prevent material in its possession or control that contains or refers to
Pulmokine Confidential Information from being destroyed or lost, or discovered, received, used, intercepted or copied by any Third Party; and 

(c) may disclose Pulmokine Confidential Information only to its employees, consultants, independent contractors, agents, Affiliates, actual or
potential Sublicensees and actual or potential acquirers, in each case solely to the extent reasonably necessary for the purposes of, and for those matters undertaken pursuant to, the performance of Licensee’s obligations and exercise of
Licensee’s rights under this Agreement; provided, in each case, that such employees, consultants, independent contractors, agents, Affiliates, Sublicensees and actual or potential acquirers are bound by terms and conditions of confidentiality
of a scope no less protective than the terms and conditions that bind Licensee hereunder. 
 For the avoidance of doubt, it is understood
that Licensee shall be liable for any breach of the confidentiality obligation under this Section 9.1 by any person or corporation to whom Pulmokine Confidential Information is disclosed by Licensee. 

9.2. Exceptions. 

Licensee’s obligations of confidentiality and non-use under Section 9.1 shall not apply to,
and Licensee shall have no further obligations with respect to, any of the Pulmokine Confidential Information, to the extent that Licensee can establish by competent proof that such Pulmokine Confidential Information: 

(a) is or becomes part of the public domain without breach by Licensee of this Agreement; 

(b) was in Licensee’s possession before disclosure by Pulmokine to Licensee and was not acquired directly or indirectly from Pulmokine, as
documented by Licensee’s written records; 
 (c) is obtained from a Third Party with no obligation of confidentiality to Pulmokine, who
has a right to disclose it to Licensee; 
 (d) is developed independently by Licensee without use of or reference to the Pulmokine
Confidential Information, as evidenced by Licensee’s written records; or 
 (e) is required to be revealed in response to a court
decision or administrative order, or to comply with applicable Laws or applicable rules of any Regulatory Authority; provided that, in each such case, Licensee shall inform Pulmokine immediately by written notice and cooperate with Pulmokine using
Commercially Reasonable Efforts either to enable Pulmokine to seek protective measures for such Pulmokine Confidential Information, or to seek confidential treatment of such Pulmokine Confidential 

  
 29 

 
Information, and in such case Licensee shall disclose only such portion of the Pulmokine Confidential Information which is so required to be disclosed. 

Any combination of features or disclosures shall not be deemed to fall within the foregoing exclusions merely because individual features are
published or available to the general public or in the rightful possession of Licensee unless the combination itself and principle of operation are published or available to the general public or in the right possession of Licensee. 

9.3. Additional Disclosure. 

Nothing herein shall prevent Licensee from disclosing any Pulmokine Confidential Information to the extent that such Pulmokine Confidential
Information is required by Law to be used or disclosed for the purposes of seeking or obtaining Regulatory Approvals of Licensed Products or is necessary or useful for seeking patent protection for Licensed Patents or Licensee Inventions. 

10. SCIENTIFIC PUBLICATIONS 
 Licensee may
not [***] without the opportunity for prior review by Pulmokine, except to the extent required by Law. In the event Licensee seeks to [***], it shall provide Pulmokine the opportunity to review and comment on any such proposed publication [***]
prior to its intended [***] Pulmokine shall provide Licensee with its comments in writing, if any, within [***] after receipt of such [***]. Licensee shall consider in good faith any comments thereto provided by Pulmokine and [***] In addition,
Licensee shall delay the submission for a period up to [***] if Pulmokine can demonstrate [***]. If Pulmokine fails to provide its comments to Licensee within such [***] period, Pulmokine shall be deemed to not have any comments, and Licensee may
publish in accordance with this Section 10 after the [***] period has elapsed. [***]. 
 Pulmokine shall not publish peer reviewed
manuscripts, or give other forms of public disclosure such as abstracts and presentation, of non-public information contained in the Licensed Technology or otherwise concerning the Compound, the Backup
Compound, the Asthma Compounds, the Biomarkers, or Licensed Products without the prior written consent of Licensee, [***], and except to the extent required by Law, provided that the foregoing shall in no way preclude or otherwise limit
Pulmokine’s correspondence with FDA or reports to NIH concerning the ongoing Phase 1A clinical trial, as described in Pulmokine’s IND 122593, until such time as IND 122593 has been transferred to Licensee or its designee, nor shall the
foregoing preclude or otherwise limit Pulmokine’s reporting to or correspondence with NIH concerning Pulmokine’s NIH SBIR Grants (R44HL102946 for PK10571, 1R43HL135910-01A1 for biomarker and
1R43HL132709-01 for asthma) until such time that such SBIR Grants have been transferred to Licensee or its designee. 

11. PRESS RELEASES 
 11.1. Joint Press
Release. 
 Within five (5) Business Days of the Effective Date, Licensee and Pulmokine shall issue a joint press release or public
announcement concerning any aspect of the development or commercialization of the Licensed Products in the Licensed Product Field in the Territory. Notwithstanding the foregoing, subject to Section 8.2(e) or 9.2(e), as applicable, either Party
may issue any public announcement that such 
  
  

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  
 30 

 
Party is advised by legal counsel is required under applicable Laws, provided that such Party provides to the other Party a copy of such press release or public announcement promptly after its
release thereof. 
 11.2. No Disclosure of Terms and Conditions. 

Except as set forth in Section 11.1, no press release or public announcement shall be made by either Party concerning the execution of
this Agreement or the terms and conditions hereof, without the prior written consent of the other Party which shall not be unreasonably withheld. Notwithstanding the foregoing, either Party may disclose the existence of this Agreement and the terms
and conditions hereof without the prior written consent of the other in connection with a due diligence process associated with any future financing by either Party or the negotiation or exploration of a possible strategic transaction involving such
Party, provided that such disclosure is made in the course of such diligence, negotiation or exploration pursuant to confidentiality obligations consistent in scope with those set forth in this Agreement. Notwithstanding anything to the contrary in
Article 8, if Pulmokine seeks to file with the U.S. Securities and Exchange Commission or the securities regulators of any state or other jurisdiction any disclosure document that describes or refers to the terms and conditions of this Agreement or
any related agreements between the Parties, then Pulmokine shall: (a) notify Licensee of such efforts, (b) provide Licensee with a copy of the relevant portions of the proposed filing at least five (5) Business Days prior to such
filing, and (c) cooperate in good faith with Licensee to obtain confidential treatment of the terms and conditions of this Agreement or such related agreements that Licensee requests to be kept confidential. No such notice shall be required
under this Section 11.2 if the substance of the description of or reference to this Agreement contained in the proposed filing has been included in any previous filing made by such Party hereunder or otherwise approved by the other Party. 

12. INDEMNIFICATION AND INSURANCE 

12.1. By Licensee. 

Licensee shall defend, indemnify and hold harmless Pulmokine, Gilead and their Affiliates, respective directors, officers, agents, successors,
assignees and employees (the “Pulmokine Indemnitees”) from and against any and all claims, liabilities, losses, costs, actions, suits, damages and expenses, including reasonable attorneys’ fees (collectively,
“Damages”) to the extent arising from any claim, action or proceeding made or brought against Pulmokine Indemnitees by a Third Party in connection with (a) the gross negligence, recklessness or intentional wrongful acts or
omissions of Licensee or its Affiliates or Sublicensees and its and their respective employees, officers, independent contractors, consultants or agents, in connection with the performance by or on behalf of Licensee of Licensee’s obligations
or exercise of its rights under this Agreement; (b) any breach by Licensee of any representation, warranty, covenant or obligation of Licensee set forth in this Agreement; (c) the development, commercialization manufacturing, marketing,
distribution, handling, possession, promotion, sale or use of the Licensed Products or any other use of the Licensed Technology by Licensee or its Affiliates or Sublicensees; or (d) any actual or alleged death, personal bodily injury or damages
to real or tangible personal property claimed to result, directly or indirectly, from the possession, use or consumption or treatment with the Licensed Products made or sold by or on behalf of Licensee, its Affiliates or Sublicensees; except in any
such case to the extent such Damages are reasonably attributable to any negligence, gross negligence, recklessness or intentional wrongful acts or omissions, willful misconduct or breach of this Agreement by Pulmokine or a Pulmokine Indemnitee. 

12.2. By Pulmokine. 

Pulmokine shall defend, indemnify and hold harmless Licensee and its Affiliates and Sublicensees and its and their respective directors,
officers, agents, successors, assignees and employees 

  
 31 

 
(the “Licensee Indemnitees”) from and against any and all Damages to the extent arising from any claim, action or proceeding made or brought against Licensee Indemnitees by a
Third Party in connection with (a) the gross negligence, recklessness or intentional wrongful acts or omissions of Pulmokine, its Affiliates or its other licensees or sublicensees and its or their respective employees, officers, independent
contractors, consultants or agents, in connection with the performance by or on behalf of Pulmokine of Pulmokine’s obligations or exercise of its rights under this Agreement; or (b) any breach by Pulmokine of any representation, warranty,
covenant or obligation of Pulmokine set forth in this Agreement; except in any such case to the extent such Damages are reasonably attributable to any negligence, willful misconduct or breach of this Agreement by Licensee or a Licensee Indemnitee.

 12.3. Indemnification Procedure. 

(a) Each Party shall promptly notify the other in the event it becomes aware of a claim for which indemnification may be sought pursuant to
this Article 12, it being understood and agreed, however, that the failure by an Indemnified Party to give prompt notice of such a claim as provided in this Section 12.3 shall not relieve the Indemnifying Party of its indemnification obligation
under this Agreement except and only to the extent that such Indemnifying Party is actually damaged as a result of such failure to give prompt notice. In case any proceeding (including any governmental investigation) shall be instituted involving
any Party in respect of which indemnity may be sought pursuant to this Article 12, such Party (the “Indemnified Party”) shall promptly notify the other Party (the “Indemnifying Party”) in writing (an
“Indemnification Claim Notice”). The Indemnifying Party and Indemnified Party shall promptly meet to discuss how to respond to any claims that are the subject matter of such Indemnification Claim Notice. The Indemnifying Party shall
assume direction and control of the defense of the claim that is the subject of the Indemnification Claim Notice (including the right to settle the Claim solely for monetary consideration) using counsel reasonably satisfactory to the Indemnified
Party, and shall cooperate as requested (at the expense of the Indemnifying Party) in the defense of such claim. 
 (b) Upon assuming the
defense of a Third Party claim in accordance with this Section 12.3, the Indemnifying Party shall be entitled to appoint counsel in the defense of the Third Party claim. Should the Indemnifying Party assume and continue the defense of a Third
Party claim, except as otherwise set forth in this Section 12.3, the Indemnifying Party will not be liable to the Indemnified Party for any legal expenses subsequently incurred by such Indemnified Party after the date of assumption of defense
in connection with the analysis, defense, countersuit or settlement of the Third Party claim. Without limiting this Section 12.3, any Indemnified Party will be entitled to participate in, but not control, the defense of a Third Party claim for
which it has sought indemnification hereunder and to engage counsel of its choice for such purpose; provided, however, that such engagement will be at the Indemnified Party’s own expense unless (i) the engagement thereof has been
specifically requested by the Indemnifying Party in writing, or (ii) the Indemnifying Party has failed to assume and actively further the defense and engage counsel in accordance with this Section 12.3 (in which case the Indemnified Party
will control the defense). 
 (c) The Indemnifying Party will have the sole right to consent to the entry of any judgment, enter into any
settlement or otherwise dispose of such Damages, on such terms as the Indemnifying Party, in its reasonable discretion, will deem appropriate (provided, however, that the Indemnifying Party shall not agree to any settlement of such action, suit,
proceeding or claim or consent to any judgment in respect thereof that does not include a complete and unconditional release of the Indemnified Party from all liability with respect thereto, that imposes any liability or obligation on the
Indemnified Party or that acknowledges fault by the Indemnified Party or that limits the Indemnified Party’s rights under this Agreement without the prior written consent of the Indemnified Party) and will transfer to the Indemnified Party all
amounts which such Indemnified Party will be liable to pay pursuant to such settlement or disposal of such claim prior to the time such payments become due by the Indemnified Party. With respect to all other Damages in connection with Third Party
claims, where the Indemnifying Party has assumed the defense of the Third 

  
 32 

 
Party claim in accordance with this Section 12.3, the Indemnifying Party will have authority to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such
Damages, provided that it obtains the prior written consent of the Indemnified Party, not to be unreasonably withheld or delayed. 
 (d) The
Indemnifying Party that has assumed the defense of the Third Party claim in accordance with this Section 12.3 will not be liable for any settlement or other disposition of any Damages by an Indemnified Party that is reached without the written
consent of such Indemnifying Party. The Indemnified Party will not admit any liability with respect to, or settle, compromise or discharge, any Third Party claim without first offering to the Indemnifying Party the opportunity to assume the defense
of the Third Party claim in accordance with this Section 12.3. If the Indemnifying Party chooses to defend or prosecute any Third Party claim, the Indemnified Party will cooperate in the defense or prosecution thereof and will furnish such
records, information and testimony, provide such witnesses including to the extent possible, former employees and attend such conferences, discovery proceedings, hearings, trials and appeals as may be reasonably requested in connection with such
Third Party claim. Such cooperation will include access during normal business hours afforded to the Indemnifying Party to, and reasonable retention by the Indemnified Party of, records and information that are reasonably relevant to such Third
Party claim, and making employees and agents available on a mutually convenient basis to provide additional information and explanation of any material provided hereunder. The Indemnifying Party will reimburse the Indemnified Party for its
reasonable out-of-pocket expenses incurred in connection with such cooperation. 

(e) The Indemnified Party shall take and shall procure that its Affiliates, Sublicensees, agents, directors, offices and employees take all
such reasonable steps and action as are reasonably necessary or as the Indemnifying Party may reasonably require to mitigate any Third Party claim subject to indemnification in accordance with this Section 12.3. Nothing in this Agreement shall
or shall be deemed to relieve the Indemnified Party of any common law or other duty to mitigate any losses incurred by it. 
 12.4.
Insurance. 
 Each Party shall maintain in full force and effect during the Term and for a period of three (3) years after
expiration or termination of this Agreement, worker’s compensation and general liability insurance coverage and, in addition Licensee shall maintain clinical trial liability and product liability insurance coverage, all in such amounts and with
such scope of coverages as are adequate to cover such Party’s obligations under this Agreement and as are customary in the industry for companies of like size and activities. Upon written request, each Party shall provide evidence of such
insurance to the other Party and ensure that the other Party will receive no less than thirty (30) days’ notice of any cancelation, non-renewal or material change in such coverage. 

13. LIMITATION ON LIABILITY 
 EXCEPT IN
THE CASE OF A BREACH OF ARTICLE 8 OR 9 OR A PARTY’S (A) WILLFUL MISCONDUCT OR INTENTIONAL BREACH OR (B) GROSS NEGLIGENCE, AND WITHOUT LIMITING EITHER PARTY’S OBLIGATIONS UNDER ARTICLE 12 OR LIABILITY OF A PARTY FOR INFRINGEMENT
OR MISAPPROPRIATION OF THE INTELLECTUAL PROPERTY RIGHTS OF THE OTHER PARTY, NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR SPECIAL, INDIRECT, PUNITIVE OR CONSEQUENTIAL DAMAGES (INCLUDING DAMAGES RESULTING FROM LOSS OF USE, LOSS OF PROFITS,
INTERRUPTION OR LOSS OF BUSINESS OR OTHER ECONOMIC LOSS) ARISING OUT OF THIS AGREEMENT OR WITH RESPECT TO A PARTY’S PERFORMANCE OR NON-PERFORMANCE HEREUNDER. 

  
 33 

 14. TERM 

This Agreement shall become effective on the Effective Date and, unless terminated earlier pursuant to Article 15, shall continue in effect
until the expiration of the last-to-expire Royalty Term (the “Term”). Upon the expiration of the last Royalty Term, the license set forth in
Section 2.1 shall become perpetual, irrevocable and fully paid-up. 
 15. TERMINATION; EFFECT OF TERMINATION

 15.1. Termination for Convenience 

Notwithstanding anything contained herein to the contrary, Licensee shall have the right to terminate this Agreement with respect to [***] on a
country-by-country basis. Any termination under this Section 15.1 shall be accomplished by Licensee giving [***] advance written notice to Pulmokine. 

15.2. Termination for Safety or Efficacy. 

Notwithstanding anything contained herein to the contrary, Licensee shall have the right to terminate this Agreement at any time in its sole
discretion either in its entirety or on a Licensed Product-by-Licensed Product or a country-by-country basis in the event of
potential safety or efficacy concerns affecting such Licensed Product. Any termination under this Section 15.2 shall be accomplished by Licensee giving [***] advance written notice to Pulmokine. 

15.3. Material Breach. 

Each Party may terminate this Agreement in its entirety immediately upon written notice to the other Party if the other Party materially
breaches its obligations under this Agreement and, after receiving written notice identifying such material breach in reasonable detail, fails to cure such material breach within ninety (90) days from the date of such notice; provided, however,
that, in the event of any dispute of whether such breach has occurred or has been cured, such termination shall not become effective unless and until such dispute has been finally resolved in favor of the Party seeking such termination. [***] in
accordance with this Section 15.1. 
 15.4. Patent Challenge. 

Pulmokine may, on thirty (30) days written notice to Licensee, terminate this Agreement if Licensee or its Affiliates or Sublicensees,
individually or in association with any other person or entity, commences a legal action (except to the extent required by Law) challenging the validity or enforceability of any Licensed Patents in any court or before any governmental authority with
authority to determine the validity or enforceability of a Licensed Patent (“Patent Challenge”). Such termination shall be effective thirty (30) days after written notice by Licensee to Pulmokine referencing this
Section 15.2, unless Licensee, within such thirty (30) days, withdraws from such Patent Challenge. Notwithstanding anything to the contrary herein, Patent Challenge does not include, and termination by Pulmokine under this
Section 15.4 is not permitted for any counterclaim made, filed or maintained by Licensee or its Affiliates or 
  

 

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  
 34 

 
Sublicensees as defendants in any patent infringement claim, demand, lawsuit, cause of action or other action made, filed or maintained by Pulmokine or Gilead or their Affiliates and/or
licensors, including where such counterclaim challenges the scope of any Licensed Patents, including without limitation any counterclaim by Licensee that the making, using, selling, offering for sale and importation of any Licensed Product is not
within the scope of the Licensed Patents. 
 15.5. Force Majeure. 

This Agreement may be terminated by the Party not affected by the event of a Force Majeure pursuant to Section 16.2. 

15.6. Insolvency. 
 Either
Party may terminate this Agreement upon written notice if the other Party is dissolved or liquidated, files or has filed against it a petition under any bankruptcy or insolvency law that is not dismissed within sixty (60) calendar days, makes
an assignment for the benefit of its creditors or has a receiver or trustee appointed for all or substantially all of its property. 

15.7. Rights Upon Certain Termination Events. 

(a) If this Agreement terminates for any reason (other than by expiration), then all rights and Licenses under the [***] granted by Pulmokine
to Licensee pursuant to [***] will terminate and all rights granted therein will immediately revert to Pulmokine, and Licensee shall promptly return to Pulmokine or its designee all [***], previously delivered to Licensee in accordance with
Section 4.6. Notwithstanding the foregoing, Licensee shall have the right to sell off any Licensed Products that have been manufactured or are in the process of being manufactured at the time of termination, provided that Licensee complies with
all of its payment, reporting and audit obligations hereunder. 
 (b) If this Agreement is terminated (whether in whole or in part) [***],
then, solely with respect to that portion of the Agreement so terminated, (i) Licensee shall, and does hereby grant to Pulmokine an exclusive, fully transferrable and sublicensable, worldwide license in and to any applicable [***] and
Licensee’s entire interests in and to any applicable [***], in each case to [***]; and (ii) Licensee shall promptly transfer and assign to Pulmokine any applicable [***]. 

(c) If this Agreement is terminated (whether in whole or in part) [***], then, solely with respect to that portion of the Agreement so
terminated, Pulmokine and Licensee shall promptly negotiate in good faith the terms and conditions of an agreement for the foregoing licenses, transfers and assignments made in favor of Pulmokine. 

 
  

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  
 35 

 15.8. Return of Confidential Information. 

Within thirty (30) days following the expiration or termination of this Agreement, each Party shall, at the request of the other Party,
(a) subject to Sections 15.7(b) or (c), deliver to the other Party, or certify the destruction of, any and all tangible Confidential Information of the other Party in such Party’s possession, and (b) to the extent practicable, remove
Confidential Information of the other Party from all databases and systems and, in those instances where removal is not practicable, segregate or otherwise indicate that such Confidential Information is restricted. 

15.9. Survival. 
 The
rights and obligations of the Parties set forth in Articles 1, 8, 9, 12, 13, 16 and Sections 3.8, 3.9, 3.12, 3.13, 6.4, 6.5, 11.2, 15.7, 15.8, 15.9, 15.10 and 16.4 shall survive termination or expiration of this Agreement. 

15.10. Other Remedies. 

15.11. 
 Termination or
expiration of this Agreement for any reason shall not release any Party from any liability or obligation that has accrued prior to such expiration or termination, nor affect the survival of any provision hereof to the extent it is expressly stated
to survive termination. Termination or expiration of this Agreement for any reason shall not constitute a waiver or release of, or otherwise be deemed to prejudice or adversely affect, any rights, remedies or claims, whether for damages or
otherwise, that a Party may have hereunder or that may arise out of or in connection with such termination or expiration. 
 15.12.
Bankruptcy Code. 
 All licenses granted under this Agreement will be deemed licenses of rights to intellectual property for purposes of
Section 365(n) of the U.S. Bankruptcy Code and Licensee as licensee under this Agreement will retain and may fully exercise all of its rights and elections under the U.S. Bankruptcy Code. 

16. GENERAL PROVISIONS 
 16.1.
Assignment. 
 Neither Party may assign this Agreement without the consent of the other Party, except as otherwise provided in this
Section 16.1. Either Party may assign this Agreement in whole or in part to any Affiliate of such Party without the consent of the other Party; provided that, such assigning Party provides the other Party with written notice of such assignment
and the assignee agrees in writing to assume performance of all assigned obligations. Further, each Party may assign this Agreement, and all of its rights and obligations, without the consent of the other Party to its successor in interest by way of
Change of Control; provided that, such assigning Party provides the other Party with written notice of such assignment within five (5) business days after such Change of Control. Notwithstanding anything to the contrary herein, Pulmokine shall
not assign this Agreement unless such assignee also assumes Pulmokine’s rights and obligations under the Gilead License and RCTR License and is assigned all of Pulmokine’s rights under the Licensed Technology that is licensed to Licensee
hereunder. Similarly, Pulmokine shall not assign its rights under the Licensed Technology that is licensed to Licensee hereunder to an Affiliate or Third Party without also assigning all its rights under this Agreement to such Affiliate or Third
Party. The terms of this Agreement shall be binding upon and shall inure to the benefit of the successors, heirs, administrators and 

  
 36 

 
permitted assigns of the Parties. Any purported assignment in violation of this Section 16.1 shall be null and void. 

16.2. Right to Set-Off. 

Without limiting Licensee’s rights under law or in equity, Licensee may exercise a right of
set-off of any and all amounts paid by Licensee pursuant to Section 2.7 as set forth therein, or paid by Licensee pursuant to Section 7.6(f) to cure a breach of the payment obligations set forth in
the Gilead License and/or RCTR License by Pulmokine against any amounts payable to Pulmokine under this Agreement. 
 16.3. Force
Majeure. 
 With the exception of Licensee’s payment obligations hereunder, no failure or delay by either Party in the performance
of any obligation hereunder shall be deemed a breach of this Agreement nor create any liability for any damages, increased costs or losses which the other Party may sustain by reason of such failure or delay of performance, if the same shall arise
from any cause or causes beyond the control of that Party, such as earthquakes, storms, floods, fires, other acts of nature, epidemic, war, riot, hostility, public disturbance, cessation of transport, act of public enemies, prohibition or act by a
government or public agency, strike or other labor dispute or work stoppage (collectively “Force Majeure”); provided, however, that the Party so prevented shall continue to take all commercially reasonable actions within its power
to comply with its obligations hereunder as fully as possible and to mitigate possible damages. The Party so prevented shall without undue delay notify the other Party in writing thereof. Should the event of Force Majeure continue for more than one
hundred twenty (120) consecutive calendar days, the Parties shall promptly discuss their further performance under this Agreement and whether to modify or terminate this Agreement in view of the effect of the event of Force Majeure. If no
agreement can be reached within thirty (30) calendar days after expiration of such one hundred twenty (120) days, the Party not affected by the event of Force Majeure may terminate this Agreement effective immediately upon written notice
to the other Party. 
 16.4. Governing Law. 

The construction, validity and performance of this Agreement shall be governed in all respects by the laws of the State of New York, excluding
its provisions regarding conflicts of law. The United Nations Convention on the International Sale of Goods shall not apply. 
 16.5.
Dispute Resolution. 
  

			
	(a)	  	        Resolution by Senior Executives. In the event of any dispute, claim, question or disagreement arising from or relating to this Agreement or the breach thereof
(“Dispute”), senior executives of each Party (“Senior Executives”) shall attempt to reach a solution satisfactory to both Parties. If the Senior Executives do not reach such solution within a period of thirty
(30) days or such longer period as the Parties may mutually agree upon, then, upon notice by either Party to the other, either Party shall be free to exercise the remedies as provided in Section 16.4(b).
		
	(b)	  	        Arbitration. Any Disputes between the Parties arising under or in connection with this Agreement not resolved through the procedures set out in Section 16.4(a), shall be
finally settled by arbitration, in New York, New York, before a panel of three (3) arbitrators having relevant experience in the biotech or pharmaceutical industries under the Rules of Arbitration of the International Chamber of Commerce
(“ICC Rules”), and the ICC Rules are deemed to be

  
 37 

			
		  	incorporated by reference to this clause. Each Party shall nominate an arbitrator, and the Party-nominated arbitrators shall agree upon the third arbitrator who will be the chair of the arbitration tribunal. If the two
(2) Party-nominated arbitrators are unable to agree upon the chair within sixty (60) days, the chair shall be selected as provided in the ICC Rules. The arbitrators shall be required to: (i) follow the substantive rules of the
applicable Law, (ii) require all testimony to be transcribed, and (iii) accompany their award with findings of fact and a statement of reasons for the decision. The arbitrator shall have the authority to permit discovery for no more than
sixty (60) days, to the extent deemed appropriate by the arbitrator, upon reasonable request of a Party. The arbitrators shall have no power or authority to (iv) add to or detract from the written agreement of the Parties set forth herein,
(v) modify or disregard any provision of this Agreement or any of the other related documents, or (vi) address or resolve any issue not submitted by the Parties. The arbitrators shall hold proceedings during a period of not longer than
forty-five (45) calendar days promptly following conclusion of discovery. The arbitration award shall be binding upon the Parties and enforceable by any court of competent jurisdiction. The arbitration award may include an award as to costs
including attorney fees.
		
	(c)	  	        Award. The award shall be made within four (4) months of the filing of the notice of arbitration, and the arbitrator(s) shall agree to comply with this schedule before
accepting appointment. However, this time limit may be extended by agreement of the Parties or by the arbitrator(s) if necessary. Judgment on the award rendered by the arbitrator(s) may be enforced in any court having competent jurisdiction
thereof.
		
	(d)	  	        Attorneys’ Fees and Costs. The arbitrator(s) shall award to the prevailing Party, if any, as determined by the arbitrators, all of its attorneys’ fees and
costs.
		
	(e)	  	        Confidentiality. The Parties undertake to keep confidential all awards in their arbitration, together with all materials in the proceedings created for the purpose of the
arbitration and all other documents produced by another party in the proceedings not otherwise in the public domain, save and to the extent that disclosure may be required of a Party by legal duty, to protect or pursue a legal right or to enforce or
challenge an award in legal proceedings before a court or other judicial authority.
		
	(f)	  	        Certain Disputes. Notwithstanding the provisions of this Section 16.4, Disputes relating to intellectual property rights, including Disputes relating to the ownership,
inventorship, enforceability, validity or scope of patent or other intellectual property rights, or other Disputes for which a Party wishes to seek injunctive or other equitable relief shall not be subject to the terms of this Section 16.4 and
may be submitted for resolution to a court of competent jurisdiction, and without the necessity of posting a bond for such Disputes seeking injunctive or other equitable relief (each, an “Excluded Claim”). The Parties agree that any
Dispute concerning an Excluded Claim that cannot be resolved by the Parties will be subject to the exclusive jurisdiction of the U.S. federal or New York state courts within the New York counties of New York, and the Parties hereby submit to, and
waive any objection to, personal jurisdiction and venue in such courts for such purpose.

  
 38 

 16.6. Compliance with Laws. 

(a) Each Party will comply in all material respects with all Laws in performing its obligations and exercising its rights hereunder. 

(b) Each Party shall perform its obligations under this Agreement in strict compliance with applicable provisions of the International Federal
of Pharmaceutical Manufacturers & Associations Code of Practice. 
 (c) Each Party shall (i) comply with anti-bribery Laws, and
(ii) adopt, implement and keep for the Term, adequate measures aimed at preventing the commission, even attempted, of conduct in violation of anti-bribery Laws by its Affiliates, directors, representatives, employees, collaborators and/or
consultants. 
 16.7. Headings. 

Headings are inserted for convenience and shall not affect the meaning or interpretation of this Agreement. 

16.8. Waiver. 
 No waiver
of any default hereunder by either Party or any failure to enforce any rights hereunder shall be deemed to constitute a waiver of any subsequent default with respect to the same or any other provision hereof. 

16.9. Notices. 
 Any and
all notices given by one Party to the other Party under this Agreement must be in writing and shall be deemed effectively given (a) upon personal delivery to the Party to be notified, (b) when sent by confirmed facsimile or electronic
transmission if sent during normal business hours of the recipient, if not, then on the next Business Day, (c) one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of
receipt, or (d) on the second (2nd) Business Day after the date deposited if mailed by first class mail, return receipt requested, postage prepaid. All notices shall be sent to the other
Party’s address as set out at the beginning of this Agreement or to the latest address of such Party as shall have been communicated to the other Party in accordance with this Section 16.8. 

Notices sent to Licensee shall be directed to the attention of : 

FSG Pulmo, Inc. 
 17 Selborne
Drive 
 Piedmont, CA 94611 

Attn: General Counsel 
 With copy
(which shall not constitute notice) to: 
 Latham & Watkins, LLP 

12670 High Bluff Drive 
 San
Diego, CA 92130 
 Attn: Steven T. Chinowsky, Esq. 

  
 39 

 Telephone:
858-523-5400 
 Facsimile: 858-523-5450 
 Notices sent to Pulmokine shall be directed to the attention of 

Pulmokine, Inc. 
 7 University
Place, B127B 
 Rensselaer NY, 12144 

Attention: Larry Zisman 

Telephone: [***] 
 With copy
(which shall not constitute notice) to: 
 Morse, Barnes-Brown & Pendleton, P.C. 

230 Third Avenue, Fourth Floor 

Waltham, MA 02451 
 Telephone: 781-622-5930 
 Facsimile: 781-622-5933. 
 16.10. Severability. 

Whenever possible, each term and provision of this Agreement shall be interpreted in such manner as to be valid and effective under applicable
Laws, but, if any term or provision of this Agreement is held to be invalid or unenforceable under applicable Laws, such term or provision shall be invalid and ineffective only to the extent of such invalidity or unenforceability, without
invalidating or making unenforceable the remainder of this Agreement. In the event of such invalidity or unenforceability, the Parties shall use reasonable efforts to seek and agree on an alternative valid and enforceable provision that preserves
the original purpose and intent of this Agreement. 
 16.11. Entire Agreement. 

This Agreement, together with all Exhibits attached hereto, constitutes the entire agreement between the Parties and shall cancel and supersede
any and all prior and contemporaneous negotiations, correspondence, understandings and agreements, whether oral or written, between the Parties respecting the subject matter hereof. 

16.12. Amendment. 
 Any
amendment or modification to this Agreement shall only be made in writing and shall only be valid when signed by the duly authorized representatives of the Parties. 

16.13. Counterparts. 

This Agreement may be executed in more than one (1) counterpart, each of which shall be deemed an original, but all of such counterparts
taken together shall constitute one and the same agreement. The exchange of copies of this Agreement or amendments thereto and of executed signature pages by facsimile transmission or by email transmission in portable document format (.pdf), or
similar format, shall constitute effective execution and delivery of such instrument(s) as to the Parties and may be used in lieu 
  

 

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  
 40 

 
of the original Agreement or amendment for all purposes. Signatures of the Parties transmitted by facsimile or by email in portable document format (.pdf), or similar format, shall be deemed to
be their original signatures for all purposes. 
 16.14. Agency. 

Neither Party is, nor shall be deemed to be, an employee, agent, co-venturer or legal representative of the other Party for any purpose.
Neither Party shall be entitled to enter into any contracts in the name of, or on behalf of the other Party, nor shall either Party be entitled to pledge the credit of the other Party in any way or hold itself out as having the authority to do so.

 16.15. Further Assurances. 

During the Term, Pulmokine and Licensee each will, at the request of the other Party, use reasonable efforts to (a) deliver to the other
Party such records, data or other documents, consistent with the provisions of this Agreement, (b) execute, deliver or cause to be delivered, all such assignments, consents, documents or further instruments of transfer or license, and
(c) take or cause to be taken all such other actions, as a Party reasonably may deem necessary or desirable in order for such Party to obtain the full benefits of this Agreement and the transactions contemplated hereby. 

[Signature page follows] 
  

  
 41 

 IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed in
duplicate by their respective duly authorized officers or representatives as of the Effective Date. 
  

					
	FSG Pulmo, Inc.	 		 	Pulmokine, Inc.
	 /s/ Faheem Hasnain
	 		 	 /s/ Lawrence S. Zisman

	By: Faheem Hasnain, CEO	 		 	By: Lawrence S. Zisman, CEO

 Solely with respect
to FSG’s obligations expressly set forth in Section 3.14: 
  

			
	FSG Bio, Inc.	 	
	 /s/ Faheem Hasnain

	By: Faheem Hasnain, CEO

  
 42 

 EXHIBIT A 

Backup Compound 
 [***] 

 
  

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  
 43 

 EXHIBIT B 

Compound 
 [***] 

 
  

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  
 44 

 EXHIBIT C 

Gilead Background Patents 
  

							
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]

  
  

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  
 45 

 EXHIBIT D 

Phase 1 Clinical Trial Plan 

[***] 
  

 

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  
 46 

 EXHIBIT E 

Pulmokine-Controlled Patents 
  

													
	 Case Type
	  	Country	 	Application
Number	 	Filing
Date	 	Publication
No. /
Patent No.	 	Pub. Date /
Issue Date	 	Title
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

  
  

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  
 47 

 EXHIBIT F 

Pulmokine-Gilead Joint Patents 
  

							
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]

  
  

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  
 48 

 EXHIBIT G 

Asthma Patents 
 [***] 

[***] 
 [***] 

 

	
	 [***]

	 [***]

	 [***]

	 [***]

	 [***]

	 [***]

  
  

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  
 49 

	
	 [***]

	 [***]

	 [***]

	 [***]

  
  

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  
 50 

 EXHIBIT H 

Biomarker Patents 
 [***] 

 

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  
 51 

 EXHIBIT I 

RCTR License Terms 
 [***] 

5.1 (a) the RCTR reserves on behalf of the Government an irrevocable, nonexclusive, nontransferable, royalty-free license for the practice of
all inventions licensed under the Licensed Patent Rights throughout the world by or on behalf of the Government 
 [***] 

 
  

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  
 52

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00290-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00290-of-00352.parquet"}]]